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ABSTRACT 
The maintenance of a proper balance between excitatory and inhibitory 
neurotransmission (E/I ratio) is crucial for correct brain development, function and 
plasticity. Through its inhibitory action, GABA (gamma-aminobutyric acid) 
neurotransmitter is the principal regulator of E/I ratio, exerting a precise modulation of 
excitatory transmission. Conversely, at the early stages of neuronal maturation, GABA 
operates as an excitatory neurotransmitter directly evoking action potentials. Then, during 
development, it acquires its typical role of brake for neuronal activity through the 
fundamental process called “excitatory-to-inhibitory switch of GABA”, the postnatal 
transition of GABA transmission from excitatory to inhibitory, directly related to the 
action of the potassium-chloride co-transporter KCC2. Defects in GABA switch have 
been largely described in neurodevelopmental disorders such as epilepsy, autism and 
schizophrenia. In this context, we have recently unveiled a new role of ATM (Ataxia 
Telangiectasia Mutated), a protein kinase involved in DNA double strand breaks (DSB) 
repair, in orchestrating the maturation of GABAergic inhibition. Here we demonstrate 
that the exposure of wild-type neurons in a “critical window” during development to an 
inhibitor of ATM kinase activity (KU), a drug already exploited as therapeutic tool in 
oncology, accelerates the excitatory-to-inhibitory switch of GABA. We show that the 
molecular mechanism underlying KU effect involves the transcription factor Egr4 and 
the epigenetic regulator MeCP2, which independently and in parallel boost KCC2 
expression both in vitro and in vivo. The resultant neuronal network exhibits a potentiated 
inhibitory synaptic transmission and appears resistant to a hyper-excitability paradigm. 
Surprisingly, we found an increased expression of ATM associated to low levels of KCC2 
in Mecp2y/- mice, the genetic model of Rett syndrome (RTT), a neurodevelopmental 
disorder associated to mental retardation. Coherently, KU treatment in Mecp2y/- neurons, 
potentiating Egr4 activity on Kcc2b promoter and restoring proper KCC2 expression, 
rescues the delayed GABA switch and counteracts the pharmacologically-induced hyper-
excitability, suggesting that increased ATM levels contribute to the generation of the 
altered neuronal phenotype in RTT. The results collected in this thesis provide new 
evidence and molecular mechanisms of ATM crucial role in the physiological 
development of central neurons and highlight ATM inhibition as a prospective 
therapeutic tool in neurodevelopmental disorders.  
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RIASSUNTO 
Il mantenimento di un corretto equilibrio tra la trasmissione neuronale eccitatoria e 
inibitoria risulta cruciale per il corretto sviluppo, funzione e plasticità del cervello. 
Attraverso la sua azione inibitoria, il neurotrasmettitore GABA è il principale regolatore 
dell’equilibrio tra eccitazione e inibizione, esercitando una precisa modulazione della 
trasmissione eccitatoria. Al contrario, nelle prime fasi dello sviluppo neuronale, il GABA 
agisce come neurotrasmettitore eccitatorio, in grado di evocare potenziali d'azione. 
Durante lo sviluppo, acquisisce il suo tipico ruolo di freno per l'attività neuronale 
attraverso il fondamentale processo chiamato "GABA switch", la transizione postnatale 
della trasmissione GABAergica da eccitatoria a inibitoria, direttamente correlata 
all'azione del co-trasportatore di potassio e cloro, KCC2. Difetti nella maturazione 
dell’inibizione GABAergica sono stati ampiamente descritti nei disordini dello sviluppo, 
tra cui epilessia, autismo e schizofrenia. In questo contesto, abbiamo recentemente 
scoperto un nuovo ruolo di ATM (Ataxia Telangiectasia Mutated), una proteina chinasi 
coinvolta nella riparazione del danno al DNA, nella regolazione dello switch del GABA. 
In questa tesi dimostriamo che il trattamento farmacologico di neuroni wild-type con un 
inibitore dell'attività chinasica di ATM (KU), un farmaco già utilizzato nella ricerca pre-
clinica oncologica, accelera lo sviluppo dell’inibizione GABAergica (i.e. GABA switch). 
Inoltre, mostriamo che il meccanismo molecolare alla base dell'effetto di KU coinvolge 
il fattore di trascrizione Egr4 e il regolatore epigenetico MeCP2, che indipendentemente 
e in parallelo promuovono l'espressione di KCC2 sia in vitro che in vivo. La rete neuronale 
risultante mostra un’aumentata trasmissione sinaptica inibitoria e appare resistente a un 
paradigma di ipereccitabilità indotta farmacologicamente. Sorprendentemente, 
dimostriamo inoltre che nel topo Mecp2y/-, modello animale della sindrome di Rett (RTT), 
un disordine dello sviluppo neurologico associato a ritardo mentale, vi è una maggiore 
espressione della proteina ATM associata a una riduzione dei livelli di KCC2. 
Coerentemente, il trattamento con l’inibitore di ATM (KU) in neuroni ottenuti da 
embrioni Mecp2y/- normalizza il ritardato sviluppo GABAergico e contrasta 
l’ipereccitabilità indotta farmacologicamente, aumentando l’attività di Egr4 sul 
promotore del Kcc2 e ripristinando quindi la corretta espressione di tale proteina. Questi 
dati suggeriscono che l’aumento di espressione di ATM contribuisce alla generazione 
delle disfunzioni neuronali tipiche della RTT. I risultati raccolti in questa tesi forniscono 
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nuove evidenze e chiariscono i meccanismi molecolari riguardanti il ruolo fondamentale 
di ATM nello sviluppo del sistema nervoso centrale (SNC) e mettono in luce l'inibizione 
dell’attività chinasica di ATM come un nuovo potenziale strumento terapeutico nei 
disordini dello sviluppo neurologico. 
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INTRODUCTION 
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Chapter 1 
 
The excitatory/inhibitory balance: implication for 
neurodevelopmental disorders 
 
The correct brain building during early development requires the appropriate 
interplay between intrinsic gene expression, molecular pathways and neuronal activity 
[1-4], with a good amount of external and environmental factors [5]. It is well accepted 
that the development of the proper brain functions depends on the maintenance of a series 
of physiological balances including i) cell growth/cell differentiation, ii) neurotrophins 
production, iii) oxidant/anti-oxidant equilibrium, iv) neurotransmitters release and v) 
pro/anti-inflammatory molecules [6-9]. Among these, the production and release of 
neurotransmitters responsible for the precise excitatory/inhibitory transmission (E/I 
balance), is crucial for a proper circuitry formation, cortical layer organization, activity-
dependent tuning of neuronal network and mechanisms at the basis of neuronal plasticity 
[10-12]. In fact, dysregulation of the E/I balance is proposed to underlie cognitive and 
social deficits typical of neurodevelopmental disorders (NDDs) [13, 14]. Coherently, 
most of NDDs such as Autism Spectrum Disorder (ASD), Intellectual Disabilities (ID), 
schizophrenia, Down syndrome, Fragile X and Rett syndrome have been associated to 
altered neurotransmitters release, aberrant circuitry formation, impaired generation of 
inhibition and GABAergic pathway alterations at different developmental stages [15-17]. 
 
 
Maturation of GABAergic inhibition and its key role in brain development 
 
In the brain, neuronal circuits consist of two classes of neurons: excitatory projection 
neurons, mainly using glutamate as neurotransmitter, and inhibitory interneurons using 
gamma-amino butyric acid (GABA) as neurotransmitter [18]. Traditionally, GABAergic 
interneurons have been considered as simple regulator of neuronal excitability, which by 
their inhibitory action operate as a brake for excitatory neurotransmission [19]. However, 
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in the last few years, the GABAergic system is getting increasing attention since among 
the crucial role in modulating E/I balance, inhibitory neurons play a vital role in the 
regulation of all the key developmental steps in brain maturation, from neuronal 
proliferation, migration and differentiation to experience-dependent organization and 
plasticity of local circuits [20-25]. Not surprisingly, alterations in GABAergic 
development have been related to many neurodevelopmental and neuropsychiatric 
disorders including schizophrenia, autism, Tourette’s syndrome, epilepsy, Down 
syndrome, Fragile X and Rett syndrome [26-29].  
The comprehension of GABAergic interneurons function and maturation is 
challenged by their heterogeneity. In fact, there are different subtypes of interneurons that 
exhibit distinct morphology, connectivity pattern and physiological properties [30]. The 
canonical classification divides interneurons into three largely independent sub-
populations based on the expression of calcium-binding proteins: parvalbumin (PV), 
somatostatin/calbindin (SST/CB) and calretinin/vasoactive intestinal peptide (CR/VIP) 
expressing neurons. In addition, diverse subtypes of interneurons innervate distinct 
domains of the post-synaptic glutamatergic cells: PV interneurons specifically innervate 
the soma and proximal dendrites, whereas SST/CB interneurons selectively innervate 
distal dendrites of target neurons. This precise spatial organization of inhibitory synapses 
along principal neurons, highlights specific functional roles carried out by diverse 
interneuron sub-populations [31].  
The formation of the GABAergic system can be divided into distinct developmental 
steps that include the generation of specific GABAergic subtypes, the migration of these 
precursors in the appropriate 
brain region, the formation of 
synaptic contacts towards 
specific post-synaptic targets 
and the activity-dependent 
adjustment of GABAergic 
synapse number and strength 
[18] (Figure 1). While the 
first stages are strongly 
regulated by genetic 
Figure 1. Time course of GABAergic circuit development in rodents. 
In the immature brain, GABA-releasing synapses are formed before 
glutamatergic contacts and represent the first form of communication 
between neurons. Modified from Di Cristo, 2007.  
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programs, synapse maturation is deeply orchestrated by experience [32]. Indeed, the rich 
pattern of innervation typical of GABAergic neurons is not completed until late 
adolescence, both in rodent and primates. During this temporal window experience-
dependent cellular and molecular mechanisms finely sculpt GABAergic network 
architecture and control maturation and plasticity of inhibitory synapses [33, 34]. The 
first molecule shown to be involved in this process is the Brain-derived neurotrophic 
factor (BDNF), which promotes the formation of GABAergic synapses and adjust their 
strength and number in both cortex and hippocampus [35]. 
More recently, it has been strongly demonstrated that GABA signaling itself can 
promote GABAergic maturation and innervation [36, 37]. This trophic action of GABA 
on cell proliferation, migration 
and differentiation lasts from the 
embryonic period up to perinatal 
period, or even adolescence, and 
is principally due to its 
depolarizing action [38].  In fact, 
at early stages of neuronal 
development, GABA acts as an 
excitatory neurotransmitter, able 
to evoke action potentials, trigger 
calcium influx and signaling [39-
41]. Then, during brain 
maturation, we assist to a change 
of GABA response polarity from 
excitatory to inhibitory in a fundamental process called “excitatory-to-inhibitory switch 
of GABA”. This change of the electrophysiological and biochemical properties of 
GABAergic transmission has been shown first in the hippocampus and then also in 
neocortex and hypothalamus [42, 43]. The switch of GABA polarity is primarily 
determined by the electrochemical gradient of Cl-, which is tightly controlled by the 
action of Na+-K+-2Cl- (NKCC1) and K+-Cl- (KCC2) co-transporters [44] (Figure 2). In 
the immature brain, NKCC1 is highly expressed and determines high Cl- intracellular 
concentration, so when GABA binds GABAA receptor, Cl
- flows out promoting 
Figure 2. Schematic diagram of the developmental switch of 
GABAergic transmission from excitatory to inhibitory. In 
immature neurons NKCC1 expression is high while KCC2 is low, 
resulting in high [Cl−]i and a depolarizing effect of GABA 
transmission. In mature neurons, the situation is reversed: the 
expression of NKCC1 is low and that of KCC2 is high, resulting 
in low [Cl−]i and inhibitory action of GABA. Modified from Ben-
Ari, 2015. 
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depolarization. Conversely, in the adult brain, NKCC1 expression is reduced and KCC2 
levels increase. The chloride extrusion operated by KCC2 establishes low intracellular 
Cl-, with a consequent inhibitory action of GABAergic currents. This developmental 
chloride gradient inversion has been demonstrated to occur in all neurons of the central 
nervous system, although its timing can significantly change in different brain regions. In 
general, evolutionarily older brain structures, such as spinal cord, medulla and thalamus, 
display a precocious neuronal generation and maturation compared to neocortex and 
hippocampus [45]. The maturation of Cl- homeostasis follows the same sequence. In the 
rat embryo for example, a strong KCC2 mRNA expression is already present at E18 in 
amygdala, thalamus and hypothalamus. On the contrary, cortex and hippocampus show 
the earliest KCC2 mRNA expression only postnatally, at post-natal day 15 (P15). In mice 
the scenario is similar: two days in advance compared to rat embryos [46]. Notably, it has 
been shown by Tyzio and colleagues that in rodent embryos, shortly before delivery, there 
is a transient excitatory-to-inhibitory switch of GABA action triggered by the oxytocin 
released by the mother. They demonstrated that this process is crucial for the proper brain 
development of offspring since maternal oxytocin inhibits fetal neurons and increases 
their resistance to insults during delivery [47].  
The developmental increase of KCC2 mRNA is tightly regulated by neurotrophic 
factors among which BDNF, that exerts a positive effect on KCC2 expression [48]. 
Conversely, mice with mutation in BDNF receptor, the tyrosine receptor kinase B (TrkB) 
receptor, show reduced levels of KCC2 in the hippocampus [49]. BDNF regulation of 
KCC2 expression is mediated by the phosphorylation of the extracellular signal-regulated 
kinase 1/2 (ERK1/2), which determines the activation of the early growth response 4 
(Egr4) transcription factor, that in turn causes the activation of the Kcc2b promoter [50]. 
Another transcription factor involved in the regulation of KCC2 expression is the 
upstream stimulating factor 1 (USF1). The interaction between USF1 and the major E-
box binding complex contributes the activation of the Kcc2b gene expression in cultured 
cortical neurons [51]. Coherently, mice deficient in USF1 display spontaneous epileptic 
seizures, suggesting the crucial role of USF1 in normal brain function [52]. It is clear that 
alterations in every step that regulates this crucial excitatory-to-inhibitory switch of 
GABA result deleterious for brain development. GABA switch dysregulation, indeed, 
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determines a failure of inhibition with a complete disruption of the E/I balance and then 
strong defects in synapse maturation, function and plasticity.  
 
 
KCC2 dysregulation in neurodevelopmental disorders: the case of the Rett 
syndrome  
 
As discussed before, alterations in the pathways that regulate GABAergic maturation 
strongly affect neuronal function leading to E/I imbalance. In this contest, KCC2 
dysregulation is one of the most impacting. For example, it has been shown that KCC2 
downregulation increases neuronal activity and contributes to seizures generation [53]. 
Coherently, loss-of-function of KCC2 has been found in both epileptic patients and in 
various animal models for epilepsy: KCC2 missense variant KCC2-R952H was identified 
in an Australian family with childhood onset febrile seizures [54], other mutations such 
as R1049C, a functional variants coding for human KCC2, might be associated with 
idiopathic generalized epilepsy [55] and in the lithium-pilocarpine induced status 
epilepticus mouse model, KCC2 mRNA and protein were found significantly 
downregulated [56]. In addition, it is largely accepted that an altered KCC2 expression is 
a common feature of diverse neurodevelopmental and neuropsychiatric disorders such as 
Fragile X syndrome, Down syndrome, autism, schizophrenia and seems to be a key 
element in the aetiopathogenesis of these diseases [27, 57, 58]. Among all these, Rett 
syndrome is the clear example of a neurodevelopmental disorder in which a dysregulation 
of the E/I balance and KCC2 lower expression lead to the most impacting neurological 
features of the pathology [59, 60]. Rett syndrome (RTT) is a devastating chromosome X-
linked neurodevelopmental disorder. In 90-95% of patients diagnosed, the pathology is 
caused by loss-of-function mutations in the Methyl-CpG-binding protein 2 (MECP2) 
gene. RTT patients display an apparently normal early development until the age of 6-18 
month, but then they undergo to a subsequent regression [61, 62]. The main symptoms 
usually become clear around 12-18 months and include loss of speech, breathing 
abnormalities, defects in motor coordination, motor disabilities and cognitive impairment 
[63]. In addition, epilepsy is present in 80% of RTT patients [64]. MeCP2 is a nuclear 
protein able to bind methylated DNA (Figure 3). It is a multifunctional modulator of gene 
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expression and its activating or repressing actions depend on the molecular context. 
Recent evidence however unveils additional roles of MeCP2 as a post-transcriptional 
regulator of gene expression through microRNA mediated mechanisms. Furthermore, the 
study of the neuronal defects 
typical of RTT has offered new 
insights on the plethora of MeCP2 
roles at different developmental 
stages, MeCP2–DNA interactions 
and the vital importance of MeCP2 
in the regulation of the E/I balance, 
circuits formation and neuronal 
plasticity [65].  
A large amount of evidence 
clearly points to alterations in the GABAergic system as key pathological features in 
RTT. Coherently, Mecp2-mutant mice, the mouse model of RTT, display a general 
impairment in GABAergic system [59, 66, 67]. The pivotal role of GABAergic 
transmission in RTT was directly provided by Chao and colleagues who demonstrated 
that the selective removal of MeCP2 from GABAergic interneurons, recapitulates most 
of the pathological phenotype of Rett syndrome [68] and then by Ure et al who rescued 
RTT disease features only by restoring MeCP2 in inhibitory neurons [69]. Accordingly, 
MeCP2 is highly expressed in GABAergic neurons and its loss-of-function determines a 
decrease of GAD65 mRNA and abnormal inter-neuron related genes expression [70]. 
Importantly, it is largely accepted that the E/I imbalance, typical of RTT, is strongly 
correlated to a failure in the maturation of the GABAergic inhibition [71]. Indeed, a recent 
study found low levels of KCC2 in the cerebrospinal fluid (CSF) of Rett syndrome 
patients [72] and Mecp2 null mice display a more depolarized reversal potential of GABA 
and reduced KCC2 levels, indicating a delay in excitatory-to-inhibitory GABA switch. 
Accordingly, Insulin-like growth-factor 1 (IGF1) treatment, by enhancing KCC2 
expression, rescues behavioural and synaptic deficits in mutant mouse models of RTT 
[73] and KCC2 overexpression in human neurons derived from RTT patients reverts 
GABAergic functional defects [60]. The clear link between KCC2 levels and MeCP2 was 
Figure 3. MeCP2 binds to chromosomes at sites of DNA 
methylation, present in gene bodies and intergenic regions of 
the genome. Missense mutations that cause Rett syndrome are 
concentrated in the MBD and NID of MeCP2. Modified from 
Cholewa-Waclaw et al, 2016. 
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further demonstrated by different recent 
studies which pointed out the direct 
regulation of KCC2 expression via MeCP2 
[60, 74]. In particular, Tang and colleagues 
showed that MeCP2 prevents the inhibition 
of KCC2 expression induced by REST. In 
fact, KCC2 gene has two repressor element-
1 sites (RE-1) near its transcription start site 
and REST, binding to these RE-1 sites, 
inhibits the expression of KCC2. In wild-
type neurons, MeCP2 occupies RE-1 sites in 
the KCC2 gene, thus preventing REST 
binding and inhibition of KCC2 expression. Whereas, in Rett neurons, that lack MeCP2, 
REST binds to the RE-1 sites and suppresses KCC2 expression (Figure 4). Because of 
KCC2 deficiency, Rett neurons show a depolarizing response to GABA.  
All together these studies highlight the importance of the GABAergic system, and 
especially the crucial role of KCC2 in the aetiopathlogy of Rett syndrome.  
 
 
Targeting GABAergic system as therapeutic tool in neurodevelopmental 
disorders  
 
The theoretical model of excitatory/inhibitory imbalance and GABAergic altered 
development as neurodevelopmental disorders origin, lays the basis for a 
pharmacological approach based on compounds acting on the GABAergic system at 
different levels: i) neurotransmitter release, ii) receptor activation and iii) maturation of 
inhibition [26]. In this scenario, many molecules are already available in clinic such as 
benzodiazepines and anticonvulsants.  
Considering the co-morbidity of neurodevelopmental disorders with epilepsy, 
anticonvulsants are widely used for the treatments of these pathologies. There are 
increasing reports showing that anticonvulsant can be useful in ameliorating some 
autistic-like behaviours [75-77]. Some of these drugs also display an anti-anxiety effect 
Figure 4. A working model of the molecular 
mechanisms underlying KCC2 deficiency in Rett 
neurons. Modified from Tang et al, 2016. 
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probably due to the increase of GABAA neurotransmission by promoting GABA synthesis 
or inhibiting its re-uptake or catabolism. This is the case of vigabatrin, a GABA 
transaminase inhibitor, that besides its anticonvulsant action is also able to improve the 
autistic behaviour of children affected by tuberous sclerosis [78].  
Less is published about the efficacy of benzodiazepines in the treatment of ASDs. 
However, it is widely accepted that gamma-aminobutyric acid agonists are effective in 
normalizing the E/I imbalance in animal models of ASDs by directly enhancing inhibition 
or indirectly reducing excitation. As an example, in the animal model of idiopathic 
autism, i.e. the BTBR mice and in the Scn1a+/- genetic model, both characterized by a 
failure of GABAA inhibition, the treatment with low doses of benzodiazepines, improve 
social and cognitive defects only by enhancing GABAergic signaling [79, 80]. Very 
interestingly, in both animal models is the selective up-regulation of α2 and/or α3 
containing GABAA receptors subunits that improves behavioural defects [79]. 
Accordingly, new studies are aimed at identifying novel agonists that can selectively 
target distinct GABAA receptors subunits to reduce side effects of GABAergic 
pharmacological treatments.  
Although by these pharmacological approaches many phenotypes have been 
ameliorated in the corresponding animal model, most of studies report only partial rescue 
of selective impairments with some defects remaining. Given that these disorders are the 
result of an aberrant development of brain networks, the timing of pharmaceutical 
treatment could be crucial in the efficiency of correcting impairments. In fact, the focus 
is now turning to early intervention in NDDs mouse models, in particular on drugs acting 
on GABAergic development and maturation [29]. In addition, it has been shown that in 
some children affected by ASDs, benzodiazepines have paradoxical effects, increasing 
anxiety and aggression [81]. The hypothesis is that GABAergic neurotransmission is still 
excitatory: enhancing GABAA mediated transmission does not always means increasing 
inhibition and could further deteriorate clinical features. Thus, the discovery that, by 
acting on NKCC1/KCC2 it is possible to indirectly modulate inhibition, opens the way 
for new therapeutic interventions aimed to correct the defect early during development. 
That is the case of bumetanide, a FDA-approved loop diuretic NKCC1 inhibitor. In a 
recent study, Tyzio and colleagues smartly demonstrated that bumetanide application one 
day pre-delivery to pregnant Fragile X mice or to VPA rats, suppresses excitatory action 
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of GABA and rescues behavioral features in the offspring in both animal models [47]. 
Bumetanide has also been tested in human ASD. Following a pivotal study [82], Ben-
Ari’s group conducted two randomized controlled trials of bumetanide in 60 and 90 
children with ASD or Asperger syndrome (3-11 years old). After three months of 
treatment, children showed significant ameliorations according to the Childhood 
Autism Rating Scale (CARS), the Clinical Global Impressions and the Autism 
Diagnostic Observation Schedule [83, 84]. Considering that bumetanide does not 
pass well the blood-brain barrier (BBB), more lipophilic bumetanide drugs have been 
developed and tested in animals [85] with promising results also in avoiding the 
diuretic side-effects due to bumetanide action on NKCC2. On the other side, 
therapeutic targeting on other components involved in chloride regulation, such as 
KCC2, is getting increased interest. Recent studies showed IGF-1 as a novel agent 
able to upregulate KCC2 expression probably via BDNF pathway [86]. Moreover, 
another recent paper described a new compound, CLP257, as a new tool to counteract 
hyperexcitability in the central nervous system (CNS). This small molecule can 
restore chloride concentrations presumably by enhancing KCC2 expression [87]. 
Thus, the study of mechanism by which chloride concentration is regulated in the 
brain is getting more attention since the great potential in rescuing pathological 
phenotypes in neurodevelopmental disorders.   
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Chapter 2 
 
DNA double-strand breaks (DSBs) and DNA damage 
response (DDR) in neuronal function and maturation 
 
DNA double-strand breaks (DSBs) are common and unavoidable genetic lesions 
essential for the survival and evolution of vertebrates. They are generated when both 
DNA strands are broken at the same position or very close to each other to allow physical 
dissociation of the double helix into two separate molecules. Despite environmental 
factors such as ionizing radiation (IR) can induce DSBs, intrinsic factors remain the major 
source of DNA damage throughout the entire genome [88]. Reactive oxygen species 
(ROS), continuously formed as by-products of cell respiration, can cause DSBs during 
all phases of the cell cycle, whereas DSBs are formed only during each S phase in 
proliferating cells by blocked DNA replication forks or DNA replication through single-
strand breaks. Importantly, DSBs induction by tissue-specific nucleases is essential for 
genetic variability in germ cells during meiosis and it is as much fundamental in the 
assembly and diversification of antigen receptor genes in developing lymphocytes. 
Coherently, defects in DSBs repair pathway lead to genomic instability, genetic and 
epigenetic changes, apoptosis and cell transformation. Thus, cells need to sense and 
respond to DSBs to survive, maintain cell diversity and function, avoid malignant 
transformation and guarantee a working immune system [89].  
The DNA damage response (DDR) is principally orchestrated by two DNA damage-
sensing kinases, ATM (Ataxia Telangiectasia Mutated protein) and ATR (Ataxia 
Telangiectasia and Rad3-related protein), which are activated by DNA damage and 
subsequently can phosphorylate hundreds of proteins including the p53 tumor suppressor 
and other tumor-suppressing and cell cycle-regulating proteins such as CHK2, BRCA1, 
NBS1 and H2AX [90-93]. ATM itself is a tumor suppressor and is required for vertebrate 
development; ATR is mainly involved in DNA replication and cell proliferation [94, 95]. 
The most studied and long-recognized outcomes of DDR signaling are the transient cell 
cycle arrest coupled with DNA repair, apoptosis, senescence or cancer [96]. Nevertheless, 
recent studies suggested other potential outcomes especially for developing and mature 
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neuronal cells. In these cells the DDR appears to yield an unexpected role in controlling 
cell differentiation programs and even in regulating neuronal activity [97]. This is a 
diverse function of DDR, completely distinct from the known DSBs response aimed in 
maintaining genome integrity, suggesting that DDR signaling, and related proteins could 
exert broader functions in neurons than previously recognized.  
 
 
Regulation of neuronal differentiation by the DNA damage response  
 
A large amount of evidence clearly suggests a link between neuronal precursor or 
stem cell (NSC) differentiation and the activation of p53-mediated DDR pathway from 
DSBs, induced by extrinsic or intrinsic events. In literature is know that IR-induced DSBs 
determines p53 acetylation in the CNS [98] and the acetylation of Lys320 supports neurite 
outgrowth in vitro and axon regeneration in vivo by 
enhancing Coronin1 and Rab13 signaling [99]. In 
addition, p53 expression regulation in NSCs located 
in the subventricular zone (SVZ) is fundamental: loss 
of p53 results in NCS proliferation, impaired 
neuronal differentiation and as consequence genesis 
of glial tumors [100]. Coherently, p53-deficient SVZ 
NSCs display increased proliferation, defects in 
maturation and altered expression of neuronal or 
glial lineage differentiation markers [101]. 
Importantly, also p21, one of the main targets of p53 
signaling, inhibits NSC self-renewal probably by 
blocking cell cycle progression (Figure 5). Thus, 
p53 deficiency could lessen p21-dependent cell 
cycle checkpoints causing increasing NSC self-
renewal and impaired cell differentiation [102].  
All together these data highlight a crucial role of p53-dependent DDR in suppressing 
NSC and multipotent precursor cell self-renewal in favour of differentiation.  
 
Figure 5. Schematic representation of 
p53/p21 signaling downstream of DSBs in 
neuronal differentiation. Modified from 
Sherman et al, 2011.  
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DNA breaks and DDR importance in neuronal physiology and disease  
 
Behaviour is strongly influenced by our experience. Neurons are able to sense and 
process changes fundamental for the survival and for the organism interplay with the 
external world. This process requires an intricate “dialogue between genes and synapses” 
in which the exposure to a new stimulus profoundly alters the morphology and 
connectivity of neural circuits by activating signaling cascades, inducing new protein 
synthesis and new gene transcription programs [103]. These changes are supposed to 
underlie the formation of long-lasting memories and adaptive responses since they are 
crucial for synaptic plasticity. These experience-dependent modifications are governed 
by the neuronal activity-regulated genes which are classified into diverse subclasses 
based on the timing of their activation following the activity-dependent stimulus. Genes 
induced first in this program, the so-called “early response genes”, are enriched for 
transcription factors among which Fos, Npas4, Nr4a1, and Egr1. These last, in turn, lead 
the expression of the so-called “late response genes”, such as Bdnf, Homer1, Nrn1 and 
Cpg15, which are induced with a longer latency [104]. Together these immediate early 
gene products regulate experience-driven changes to synapses including synaptogenesis, 
neurite outgrowth, synaptic strength and maturation and the crucial E/I balance [105]. 
However, the precise mechanism that coerces early response genes in the absence of a 
stimulus, and those that trigger their rapid induction, are poorly understood.  
Importantly, recent studies pointed out that diverse paradigms of neuronal 
stimulations, such as the exposure of  
mice to physiological learning 
behaviours, determine the formation 
of DSBs [106, 107]. Madabhushi and 
colleagues, discovered that these 
activity-induced DSBs are restricted 
to few loci through the entire genome 
enriched for the early response genes 
Fos, Npas4, Egr1, and Nr4a1 (Figure 
6). The mechanism underlying this 
paradigm seems to depend on a Type 
Figure 6. Neuronal activity triggers the formation of Topo 
IIβ-mediated DNA breaks in the promoters of a subset of 
early-response genes that are crucial for experience-driven 
synaptic changes. Modified from Madabhushi et al, 2015. 
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II topoisomerase, Topo IIβ, which is essential for the imminent induction of the early 
response genes. In fact, Top2b null mice display lower activity-induced DSBs and then a 
decrease induction of early response gene. Thus, engineering targeted DSBs in the 
promoters of these genes promote their induction even if Top2b is knocked down [107]. 
Together, these results highlight the importance of DSBs formation in the induction of 
early response genes following neuronal activity and reveal new role of DSBs and related 
signaling in shaping synaptic plasticity and in controlling neuronal function and 
behaviour. In addition, it has been shown that Topo IIβ-mediated DSBs induce gene 
expression also in other cell types and in response to diverse stimulations such as 
androgens, estrogen and insulin [108, 109]. Thus, this paradigm might be an important 
and conserved program to rapidly induce gene expression. While early response genes 
changing in expression are governed by DSBs formation and related repair mechanisms, 
a recent study showed that Bdnf and other late response genes dynamics, are regulated by 
active demethylation through the base-excision repair pathway [110]. Considering the 
crucial role of activity-dependent genes expression in neurons, defects in DNA repair 
have important pathophysiological implications. In facts, loss-of-function mutations in 
different proteins implicated in DDR generate devasting neurological disorders [111] 
(Figure 7). That is the case of ATR-Seckel syndrome, a complex pathology generated by 
mutation in ATR gene and characterized by microcephaly and progressive aging; LIG4 
syndrome, a microcephaly due to defects in p53 dependent pathway and Ataxia 
Telangiectasia (A-T), caused by mutations of ATM, that I will extensively describe in the 
next chapter.  
Figure 7. Modified from Madabhushi et al, 2014 
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Furthermore, the new role of DSBs in governing the activity-induce gene dynamics 
suggests that alterations in any step of DSBs, from the formation to the repair, might have 
a strong impact on cognitive performance. About that, a recent study discovered 
homozygous mutations in TDP2 gene in patients with a neurological phenotype 
characterized by seizures, intellectual disabilities and ataxia [112]. TDP2, the tyrosyl-
DNA phosphodiesterase 2, is an enzyme specialized in repairing the ‘abortive’ TOP2-
induced DSBs. Also, DNA repair defects and changes in the expression of protein 
involved in DDR pathway have been largely descried in neurodegenerative disorders such 
as Alzheimer disease (AD), Parkinson disease (PD) and Huntington’s disease (HD). The 
hallmark symptom of Alzheimer’s disease is cognitive decline; in 1987, Robinson and 
colleagues demonstrated that alkylation damage is inefficiently repaired in cells obtained 
from patients with AD [113]. They suggested that this could be the cause of late-onset 
familial Alzheimer’s disease and the associated damage to the CNS. Starting from this 
pioneering publication, many other studies have shown an increased DNA damage and 
decreased DNA repair in both patients and mouse models of AD [114]. Recently, 
Suberbielle and co-workers corroborated this hypothesis showing that transgenic mice for 
human amyloid precursor protein (hAPP), a well described mouse model of AD, 
displayed increased neuronal DSBs at baseline and more severe and prolonged activity-
induced DSBs after exploration [106]. They demonstrated that i) the suppression of 
aberrant network activity in hAPP mice normalized their levels of DSBs and ii) Aβ 
oligomers caused DSBs to form in primary neuronal cultures [106], indicating that 
transient increases in neuronal DSBs are an integral component of physiological brain 
activity and that Aβ exacerbates DNA damage by eliciting aberrant synaptic activity. The 
damage induced by this high amount of DSBs in AD is exacerbated by a defective DDR. 
In fact, it has been demonstrated a failure of ATM function and consequently a reduced 
DDR efficiency in both AD mouse model and human AD tissues [115], suggesting that 
ATM deficiency and altered DDR could be important contributors to the 
neurodegeneration in AD. Oxidative stress and DNA damage are also implicated in PD, 
in which the hypersensitivity to DNA-damaging agents seems to be one of the major 
mechanisms involved in neuronal death [116]. Moreover, HD, a neurodegenerative 
syndrome caused by mutations of the IT15 gene encoding for the huntingtin protein, 
displays a strong impairment in DDR pathway. In fact, HD human skin fibroblast showed 
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an abnormally low rate of recognized DSBs and irradiated HD cells present a moderate 
yield of unrepaired DSBs due to a delayed nucleo-shuttling of phosphorylated forms of 
the ATM kinase probably caused by the binding of ATM to mutated huntingtin in the 
cytoplasm [117]. Coherently, Lu and colleagues demonstrated an increased ATM 
signaling in cells derived from HD mice and in brain tissue from HD mice and patients 
[118]. Also, they showed that the genetic reduction of Atm gene dosage by one copy 
ameliorated multiple behavioural deficits and partially improved neuropathology of HD 
mice [118], suggesting ATM may be a useful therapeutic target for HD. 
All together these findings highlight the enormous importance of studying whether 
neurological defects arise from defective DSBs and alteration in proteins involved in 
DNA repair pathways and open the way to new possible pharmacological targets in 
neurological diseases.   
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Chapter 3 
 
Ataxia-Telangiectasia 
 
Ataxia-Telangiectasia (A-T) was initially described by Syllaba and Henner in 1926, 
which documented the first case of A-T in literature. Fifteen years later, the syndrome 
was again defined by Louis-Bar who described a nine-old boy with progressive cerebellar 
ataxia and cutaneous telangiectasia [119]. Consequentially, the disease was called Louis-
Bar syndrome for a period. The complete description of the pathology was finally 
provided by Boder and Sedgwick in 1957, which named the syndrome Ataxia-
Telangiectasia (A-T), because of the two most visible features of the disease [120]. Only 
in 1988, using genetic linkage analysis of 31 A-T families, Gatti and colleagues first 
localized a gene(s) for A-T in chromosomal region 11q22-23 [121]. This finding allows 
many laboratories to perform extensive positional cloning studies. Thus, the search for 
A-T gene(s) was reduced to less than 500 kilobases [122]. But not before 1995, one single 
gene was identified as the cause of the disease [123]. The defective gene in A-T was 
subsequently named ATM (A-T mutated). This gene occupies 160 kb of the entire 
genomic DNA and encodes a 12 kb transcript of 66 exons [124]. 
 
 
General features of Ataxia-Telangiectasia (A-T) 
 
A-T is a hereditary progressive neurodegenerative rare disorder, with an estimated 
frequency between 1/40,000 and 1/100,000 live births [125]. It is known that many A-T 
cases, especially those who die at a young age, are never diagnosed. Therefore, this 
pathology may be much more prevalent. It is estimated that ~1% of the general population 
in the United States carries defective A-T genes (according to the A-T Project 
Foundation). The classical A-T phenotype is caused by homozygosity or compound 
heterozygosity for ATM alleles, which truncate or completely inactivate the protein via 
missense mutations [126]. Despite the functional uniformity of the mutations, there is a 
consistent variability in the age of onset and in progression of symptoms. Milder forms 
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of A-T, which are characterized by later onset and slower progression, are associated with 
leaky splicing mutations or promoter defects that leave residual amounts of functional 
ATM protein [127].  
A-T generally appears early in childhood: around the age of three patients begin to 
have trouble in walking independently [128] and by the end of the adolescence become 
wheelchair bound. Besides the classical A-T signs which are ataxia (lack of muscle 
control) and telangiectasia (abnormal dilation of capillary vessels), A-T includes a wide 
range of symptoms, among which: progressive dysarthria (dysphasic disorder of language 
characterized by difficulty in articulating words), choreoathetosis (abnormal movements 
of the body), oculomotor apraxia (incapability to follow moving objects), growth 
retardation, genomic instability that caused an increased cancer susceptibility, 
hypersensitivity to ionizing radiation and sterility [129-131]. 
A progressive and massive cortical cerebellar degeneration related mostly to the 
Purkinje and the granule cells has been described in patients [132] and it is associated to 
an inexorable loss of cerebellar function. In addition, autopsies and magnetic resonance 
imaging (MRI) studies have shown significant thinning of the cerebellum and cerebellar 
atrophy [133]. Finally, degenerative changes in other CNS regions appear during patients’ 
life among which dentate and olivary nuclei, basal ganglia, brain stem and spinal cord. 
Despite the neurodegeneration, A-T also affects the immune system. In patients an 
absence or a reduction of various immunoglobulins including IgA and IgE isotypes, IgG2, 
IgG4 has been described [134]. These alterations are associated with thymic hypoplasia, 
loss of follicles in the lymph nodes, absence of delayed hypersensitivity reaction and slow 
formation of circulating antibodies. This state of immune deficiency explains the obvious 
susceptibility of A-T patients to recurrent lung infections and bronchiectasis [135].  
A-T is fatal, affected individuals usually die by their twenties with few surviving into 
thirties. The cause of death is usually pneumonia or chronic lung disease, which may 
result from defects in chewing and swallowing caused by the progressive neurological 
impairment [136]. Neoplasms are frequent, and they are the second leading cause of death 
[137]. In clinic, diagnosis of A-T is commonly based on the recognition of the classical 
hallmarks of the pathology: progressive ataxia and telangiectasia. A more precise 
diagnosis is provided by the analysis of the cellular phenotype of A-T. In fact, cell lines 
derived from patients show characteristic abnormalities, including defective growth, 
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increased serum growth factor requirements, premature senescence, major sensitivity to 
IR and failure to establish effective cell-cycle arrest after genotoxic insult [138]. This 
method is more accurate, but it requires time and effort for the generation of the cell-line.  
No curative strategy for A-T exists and treatments are focused on slowing the 
progression of the neurodegeneration as well as other approaches are involved in fighting 
tumors. However, since it seems that oxidative stress may be one of the most important 
causes of degeneration in A-T, potential therapies based on antioxidant could be 
promising [139].  
 
 
Cognitive defects in A-T patients 
 
As previously described, the main neurological defects associated to A-T patients 
consist in the progressive cerebellar ataxia and in symptoms involving the extrapyramidal 
pathways such as ocular apraxia and a progressive axonal somatosensory polyneuropathy 
with an onset peaking around eight years. However, a cognitive phenotype was also 
described in A-T.   
It is widely accepted that cerebellum participates in the organization of higher order 
functions and cerebellar cognitive affected syndrome (CCAS) is characterized by deficits 
in executive function, linguistic processing, working memory and spatial cognition, 
resulting in overall intellectual impairment [140]. The intellectual impairment reported in 
cerebellar and cerebrocerebellar diseases differs in term of behavioural and cognitive 
phenotype depending on the pathology [141]. Moreover, the timing and the onset of the 
condition influence the functional outcome with most important impact in the early stage 
of development. That is the case of A-T, in which the mutation affects the CNS since the 
early embryonic stage. Coherently, even pediatric patients display executive function 
defects, acquire expressive and receptive language impairments, visuospatial disabilities 
and verbal working memory defects [142]. Despite these defects could be entirely 
ascribed to cerebellar syndrome, patients also display defects in attention, late learning 
and memory that cannot be completely attributed to cerebellum. Accordingly, Nora D. 
Volkow and colleagues [143] have conducted a study to measure brain glucose 
metabolism by positron emission tomography and 18-fludeoxyglucose in homozygous 
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and heterozygous patients comparing to healthy controls. By these analyses, they showed 
that not only homozygotes but also heterozygotes have a reduced glucose metabolism in 
some brain regions including the hippocampus, the brain structure fundamental for 
memory and learning functions. This suggests that in homozygous and even in 
heterozygous asymptomatic patients, mutations of ATM gene impact not only cerebellar 
functions but also properties of different brain regions such as hippocampus. 
In this scenario, Mostofsky and colleagues [144] demonstrated a significantly lower 
verbal IQ and considerable problems with judgment of duration in 17 A-T patients. These 
neurological defects flank speech abnormalities, difficulty in coordination and timing. 
Therefore, another team has recently studied a group of eight affected children to 
understand whether they possess global learning disabilities and/or cognitive impairment 
or language specific defects and if they were subjected to a progressive course [145]. The 
results of all of these studies showed that almost all patients have progressive cognitive 
deficit and that the IQ of younger affected, tested with a non-verbal test, seems to fall into 
the average (IQ=100) while that of older fits in values between 57 and 83. The analysis 
of the neuropsychological profile of all the patients, however, showed significant defects 
of attention, verbal memory, non-verbal memory, late learning and fluency of speech. 
 
 
Atmy/y, a mouse model of A-T 
 
Several model systems have been generated for an appropriate investigation of A-T, 
but none recapitulate all the features of the pathological phenotype. Most of these lines 
have been developed in mice. Although Atm-deficient mouse models manifest much of 
the phenotype described in A-T patients, the wide consensus is that they do not exhibit 
the most debilitating hallmark of A-T, neurodegeneration [146]. Independently developed 
Atm-deficient mouse models may vary in their phenotypic manifestations due to different 
mutagenesis strategies and/or genetic backgrounds, however they all display 
immunodeficiency and immune system defects including T-cell maturation, growth 
retardation, germ cell dysfunction and infertility, cancer predisposition and increased 
sensitivity to ionizing radiation (IR) [134, 147, 148].  
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Among all the genetic mouse model generated for A-T, that generated by Borghesani 
and colleagues, the Atmy/y, is the closest to A-T pathological phenotype [149]. Atmy 
mutation was generated by replacing the exons 50-52 of human ATM gene (the Rad-3 
homology domain), with a neor (neomycin-resistance) gene in murine ES cells (Figure 
1). This mutation was transmitted into mice. Atmy/y allows to produce two alternative 
transcripts. In Atmy transcript I, the splicing of exon 49 to the exogenous exon results in 
a frameshift and a stop codon. In Atmy transcript II, exon 49 is directly spliced to 53, and 
the resulting protein presents a working phosphatidylinositol 3-kinase domain. Although 
these aberrant transcripts can be proved by RT-PCR in Atmy/y tissues, neither full-length 
nor partial ATM-immunoreactive protein bands has been detected [149]. Likewise, in A-
T patients with missense or in-frame deletions in which altered ATM protein products 
may be found [150]. Atmy/y mice display pathological phenotypes still present in other 
Atm-deficient mouse models including immunodeficiency, infertility, growth-retardation 
and they are prone to develop thymic lymphomas. In contrast to others, Atmy/y mice also 
exhibit some aspects of cerebellar pathology reported in A-T patients such as histological 
changes in the cerebellum as reduced molecular layer thickness, abnormalities in Purkinje 
cells dendritic arborization and localization. Nevertheless, no evidence for cerebellar 
degeneration has been detected in this mouse model with age [149]. Accordingly, Atmy/y 
mice exhibit a range of neurological abnormalities and a reduced performance in motor-
learning tests. For example, the use of rota-rod testing to measure motor function have 
shown that wild-type mice have significantly longer latencies to falling-off than mutant 
animals. They also fail to improve with repeated trials on accelerating, rotating rod. 
Moreover, spontaneous locomotor activities, measured using the standard open field test, 
is also significantly reduced in Atmy/y mice [146].  
All these data demonstrated that Atmy/y mouse model is the most suitable for the study 
of A-T in mice because it recapitulates most and more severe of A-T pathological 
phenotype.    
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Chapter 4 
 
ATM (Ataxia Telangiectasia Mutated) 
 
The structure of ATM  
 
ATM is a large Ser/Thr-protein kinases of approximately 350 kDa. It belongs to the 
superfamily of phosphatidylinositol 3-kinase-related kinases (PIKKs). The PIKK family 
also includes six other protein kinases among which ATR and DNA-dependent Protein 
Kinase (DNA-PK), that show sequence homology to phosphatidylinositol 3-kinases 
(PI3Ks) [135, 151]. ATM contains diverse characteristic domains: an amino-terminal 
substrate-binding domain (HEAT repeat domain) that binds to some known substrates 
such as Nijmegen Breakage Syndrome-1 (NBS1), p53 and Breast Cancer Susceptibility 
Protein-1 (BRCA1), the deletion of this crucial binding domain inactivates the protein 
[23]; a FAT domain, so named because it is a common motif in other related proteins 
such as FRAPP/ATM/TRRAP, which interacts with ATM's kinase domain to stabilize 
the C-terminus region of ATM itself; the kinase domain (KD); the PIKK-regulatory 
domain (PRD) and an extreme C-terminal FATC domain that represents an ordinary 
carboxy-terminal amino-acid sequence usually located near the termini of the protein 
[152, 153]. These last two domains regulate the KD (Figure 8A). Although no structure 
for ATM has been solved, it seems that the overall shape of ATM is very similar to DNA-
PKcs and composed by a head and a long arm able to wrap the double-stranded DNA 
after a conformational change [154] (Figure 8B). 
Figure 8. A) Graphical representation of the domain organization and the total number of residues for 
each PIKK family member. B) EM (electron microscopy) structure of ATM. Modified from Rivera-Calzada 
et al, 2015.  
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ATM governs genomic integrity and controls cell-cycle check points  
 
Until now, the best-known function of ATM is the DNA repair induced by DSBs. It 
is at the peak of a signaling cascade that responds to DNA double-stranded breaks (DSBs) 
and it is required to coordinate the resulting cellular response [155]. ATM is also 
necessary for processing the physiological DNA strand breaks that happen during 
meiosis, immune system maturation and for telomere maintenance. In fact, 
hypersensitivity to ionizing radiation (X-rays and γ-rays), known to break DNA, was 
reported in A-T patients after radiotherapy for cancer [156] and in A-T cell cultures [157].  
ATM exhibits increased kinase activity in response to IR or to the radiomimetic 
compound neocarzinostatin but not to UV irradiation [91]. UV irradiation induces 
relatively less significant DNA damage, whereas IR usually produces severe Double-
Strand Breaks (DSBs) inside the genome.   
ATM undergoes auto-phosphorylation after DNA damage (Figure 9). Upon detection 
of DSBs, the MRE11-RAD50-NBS1 (MRN) complex is assembled at the DNA damage 
site and then ATM protein is recruited to 
the lesion site by association with the 
MRN complex [158, 159]. This 
association is necessary for proper DNA 
Damage Repair (DDR) and disruption of 
the complex may cause profound 
physiological deficit. The importance of 
the relationship between ATM and the 
MRN complex is unveiled by the 
similarity of two other disorders related to 
AT: Nijmegen Breakage Syndrome by 
NBS-1 mutants and A-T Like disorder 
(ATLD) by MRE11 mutants [160, 161]. 
These two pathologies are distinct from A-
T although they share many close clinical 
symptoms and cellular hallmarks. 
Subsequently, MRN complex acts as an 
Figure 9. ATM signalling pathway in response to 
DNA double-strand breaks. Modified from 
McKinnon, 2004. 
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adaptor for ATM’s auto-phosphorylation at Serine 1981 in human (S1987 in mouse). This 
phosphorylation is fundamental to obtain the dissociation of non-functioning ATM dimer 
into two active monomers [158, 159]. Once activated, ATM can phosphorylate 
downstream DDR targets among which the histone variant H2AX, present within 
chromatin, that is converted into γH2AX by ATM dependent phosphorylation. This 
seems to be the initial signal for subsequent accumulation of DNA-damage-response 
proteins including BRAC1 (breast cancer susceptibility protein-1), MDC1 (Mediator of 
DNA-damage Checkpoint protein) and 53BP1 (p53-Binding protein), which together 
with the multiprotein complex previously formed, facilitate the cellular response to DSBs 
[162]. Importantly, MDC1 binds to γH2AX via its BRCA1 C-terminal (BRCT) domain 
and represents a sort of “master regulator” and initiates the subsequent repair of DSBs 
[163]. 
Besides this fundamental role in DNA 
repair, ATM is also essential in regulating cell-
cycle checkpoints (Figure 10) [164]. When the 
DNA double-stranded breaks (DSBs) occur, the 
inhibition of the cell cycle through the 
activation of cell-cycle checkpoints is needed 
for survival [165]. Cell-cycle checkpoints are 
members of a surveillance system essential to 
maintain genomic integrity after DNA damage 
and to avoid the accumulation of mutations due 
to DNA breaks: if there are any abnormalities, 
they result in programmed cell death 
(apoptosis) to eliminate the damaged cell, or 
they directly arrest the cell cycle to prevent replication of potentially damaged DNA. The 
cell cycle can stop at different stages: i) before or during S phase, to prevent the DNA 
replication; ii) before mitosis (in G2 checkpoint) to forestall aberrant segregation of 
damaged chromosomes. Accordingly, failure of these mechanisms results in genomic 
instability and cancer predisposition [166]. Because several ATM substrates are key 
effectors of the cell cycle, cells from A-T patients display defective cell-cycle checkpoints 
[167-169]. ATM protein is directly involved in cell cycle arrest at both G1 and S phases. 
Figure 10. Scheme of ATM and the cell-cycle 
checkpoint response to double-stranded breaks. 
Modified from van Gent et al, 2001.  
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The tumor suppressor protein p53 is required for the G1 arrest and its phosphorylation is 
mediated by ATM on serine 15 after detection of DNA damage. Phosphorylated p53 acts 
as a transcription-factor that activates the production of p21 (also known as CIP1 or 
WAF1), which in turn inhibits cyclin E and its partner CDK2 that together form a 
complex required for progression of the cell cycle from G1 to S phase [170]. Also, Chk2, 
another target of ATM, is phosphorylated in this process. Once activated, it 
phosphorylates p53 on serine 20 [171]. ATM also plays a key role in the cell-cycle arrest 
at S-phase, in which starts DNA replication. In fact, one of the first finding and most 
important abnormality that characterizes ATM-deficient cells is a failure to arrest DNA 
synthesis after ionizing radiation. This phenomenon was named Radio-resistant DNA 
Synthesis (RDS). The S-phase checkpoint arrest depends on a new substrate p95/NBS1. 
It is a distinct process from G1 checkpoint and does not require p53 [172]. Upon DSBs, 
activated ATM phosphorylates NBS1 on serine 343. As a result of this NBS1 
phosphorylation, the new DNA synthesis site (Replicon) will be inhibited and the cell 
will be stopped at S-phase [173]. To summarize, upon detection of DSBs, nuclear ATM 
is activated by auto-phosphorylation and then starts a series of complex programs of cell 
cycle arrest and/or DNA repair that are necessary to maintain the integrity of the genome.   
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Chapter 5 
 
Multiple role of ATM protein kinase: beyond the DNA 
damage response 
 
ATM’s involvement in DDR clearly explains many pathological hallmarks of A-T 
disease including cancer predisposition, hypersensitivity to ionizing radiation, 
immunodeficiency and infertility [135]. However, neurological symptoms such as ataxia, 
speech defects and abnormal body movements are still difficult to explain. Indeed, when 
we regard the CNS phenotype of the ATM-mutant brain, we must conclude that the 
related pathological mechanism is certainly more complex than a deficit associated only 
to the DNA repair mechanism [126]. Furthermore, without ATM, cells can still repair the 
DNA but through processes more time consuming [174]. Anyway, this delay and the 
enhanced stress related, do not seem enough to explain the neurodegeneration in ATM-
deficient humans and in A-T animal models. In accordance, ATM mutations in mice 
impact on DNA damage response, inducing only mild neurological symptoms [175]. One 
possible explanation is that ATM may play additional roles in cells of developing and 
mature CNS in different districts. In line with this hypothesis, many studies revealed the 
presence of ATM in the cytoplasm, and not only in the nucleus as previously described, 
playing different, but still important role, then DDR. Thus, while the main 
presence/function of ATM in the molecular pathways following DNA damage has been 
explored in depth, many recent studies have demonstrated ATM’s involvement in a wider 
spectrum of cellular activities especially in neurons [176]. 
 
 
ATM as an oxidative-stress sensor 
 
Oxidative stress is defined as a disturbance in the balance between the production of 
reactive oxygen species (free radicals) and antioxidant defences [177]. Most of the 
cellular DNA-damages are due to normal metabolic by-product and not to IR or 
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exogenous radiomimetic chemicals. Indeed, oxidative stress produced by endogenous 
metabolism causes, at least in part, the constitutive low-level DNA damage response often 
detected in cultured cell [178]. Because of their intense metabolic activity, neurons are 
subjected to a considerable oxidative stress, and the deregulation of these processes has 
been associated with various neurodegenerative conditions [179].  
There is consistent evidence that oxidative stress contributes to the A-T phenotype. 
Accordingly, oxidative stress has been recorded in patients with A-T, in A-T cell cultures 
and in brain and tissues of Atm deficient mice [180, 181]. Moreover, ATM-deficient cells 
are hypersensitive to oxidative damage and radical scavengers can alleviate this 
sensitivity [182]. Thus, not surprisingly, neuronal oxidative stress has been suggested as 
key player in the neurodegeneration process occurring in A-T [183, 184]. All these 
findings suggest the involvement of ATM in oxidative stress regulation, which goes 
beyond the “classical role” in DDR. In this scenario, Guo and colleagues smartly revealed 
that oxidation can directly induce ATM activation in the absence of DSBs [185]. In fact, 
whereas after DNA breaks, S1981 phosphorylation of ATM leads to ATM activation and 
dimer dissociation, under oxidation, disulphide bonds are formed resulting in covalent 
linkages between the subunits of the dimer. In this configuration, kinase activity is found 
to be activated. Surprisingly this newly discovered activity is independent of S1981 state 
of phosphorylation and H2O2-activated ATM can phosphorylate p53 and CHK2, two 
traditional ATM targets [185]. Thus, ATM acts as an oxidative sensor and controls redox 
homeostasis through two main pathways: i) via MAPK pathway and ii) via rerouting of 
carbon metabolism. Once activated, ATM triggers JNK-cjun pathway [186], which is 
known to be involved in intracellular redox homeostasis, and regulates central carbon 
metabolism by promoting the phosphorylation of Hsp27 which in turn activates the 
Pentose Phosphate pathway and stimulates NADH production [187, 188]. NADH helps 
in protecting cells against ROS (reactive oxygen species) toxicity because it is a cofactor 
of many antioxidants enzymes.  
This emerging role of cytoplasmic ATM is believed to be crucial in neurons, in which 
oxidative stress is higher than in another cells types [189]. Thus, cytoplasmic ATM seems 
to play a neuroprotective activity and the deregulation of this pathway may be one of the 
main causes of neurodegeneration occurring in A-T patients. 
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ATM mediates epigenetic regulation  
 
Recent studies have shown another function of ATM probably involved in the 
determination of the A-T phenotype. By its interaction with HDAC4, a member of Class 
IIa histone deacetylases (HDACs), ATM seems to act as an epigenetic regulator. It’s 
widely known that class I and class IIa HDACs play important roles in brain development 
and neuronal survival [190, 191]. HDAC4 is abundant in neurons, especially in Purkinje 
cells, where it is predominantly cytoplasmic. HDAC4-deficient mice show a significant 
cerebellar atrophy and Purkinje cells display structural and density abnormalities 
compared to wild-type. HDAC4 localization depends on its phosphorylation state: the 
dephosphorylated form accumulates in the nucleus whereas it must be phosphorylated to 
stay in the cytoplasm [192]. Li J. and colleagues [193], discovered that in samples from 
A-T patients and Atm-null mice, HDAC4 localizes predominantly in the nucleus and this 
nuclear accumulation is ATM-dependent. In fact, PP2A (Protein Phosphatase 2), the 
HDAC4 phosphatase, is down-regulated by ATM mediated phosphorylation. Thus, in 
ATM deficiency, there is an increased activity of PP2A on HDAC4 that cause HDAC4 
cytoplasmic deprivation and nuclear accumulation. Consequently, in ATM-deficient 
neurons global histone acetylation is decreased meaning a closed chromatin configuration 
and a reduced general transcription. Importantly, HDAC4 directly silences the 
transcriptional activity of two pro-survival transcription factors: MEF-2 (myocyte 
enhancer factor 2) and CREB (cAMP response element-binding protein) [194, 195]. The 
authors also observed a decreased transcription of other crucial neuronal genes such as 
Bdnf, NR2a and Nrxn. Thus, the dysregulation of this pathway determines genome-wide 
alterations in neurons that maybe contribute to neurodegeneration [193].  
The same group has recently reported that also histone H3K27 tri-methylation 
(H3K27me3) mediated by polycomb repressive complex 2 (PRC2), also plays a 
fundamental role in the development of A-T pathological phenotype [196]. Indeed, EZH2 
(enhancer of zeste homolog 2), that is a core catalytic component of PRC2, it has been 
found to be a new ATM kinase target. ATM-mediated S734 phosphorylation reduces 
EZH2 stability. Thus, in ATM deficiency, PRC2 formation is elevated along with 
H3K27me3. This change of H3K27me3 chromatin-binding pattern is strictly related to 
cell-cycle re-entry and cell death of Atm-deficient neurons [196]. Furthermore, 
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knockdown of EZH2 rescues Purkinje cell degeneration and behavioural alterations in 
ATM deficient mice, pointing that EZH2 hyperactivity as another key factor in A-T 
neurodegeneration. 
 
 
Role of ATM in insulin signaling pathways 
 
Another interesting role of ATM is its involvement in insulin signaling pathways. For 
the first time, Yang and Kastan demonstrated that ATM kinase activity increases 3-fold 
in response to insulin in rat 3T3-L1 cells that have been differentiated into adipocytes 
[197]. Moreover, the phosphorylation of 4E-Binding Protein 1 (an insulin-responsive 
cytoplasmic protein member of a family of translation repressor proteins) at Ser111 is 
mediated by ATM and promotes mRNA translation [197]. Thus, cells lacking ATM 
display a decreased insulin-induced dissociation of 4E-BP1 from eIF-4E with a 
consequent dysregulation in the insulin-pathway that controls translation initiation.  
More recently, it has been demonstrated that ATM is the main activator of PKB/Akt 
in response to insulin or Ɣ-radiations. This effect is mediated by ATM 
phosphatidylinositol 3-kinase domain that directly phosphorylate Akt at Ser473 (Figure 
5), causing the full activation of this transcription factor. Coherently, cell lines derived 
from A-T patients display altered Akt pathways and Atm-null mice show a drastic 
decrease of Akt phosphorylation in Ser 473 [198, 199]. Moreover, A-T patients are insulin 
resistant and this could be partially explained by the lack of full Akt activity [200]. 
Through the response to insulin and other growth factors, Akt plays a key role in many 
physiological processes such as protein translation, cell proliferation and survival, 
glucose uptake [201]. Considering its pro-survival function, the dysregulation of Akt 
pathways plays a pivotal role in cancer development [202] and in this scenario ATM 
activity on Akt acquires a potential therapeutic effect. It has been demonstrated that 
blocking ATM activity in cancer cells with overactivated Akt suppresses cell proliferation 
and induces apoptosis.  
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ATM implication in synaptic vesicles behaviour in neurons   
 
A very interesting observation about the role of ATM besides DDR regards its 
association with cytoplasmic vesicles, particularly with synaptic vesicles in neurons. In 
1996, Lakin and colleagues found that ATM co-fractionate and co-localize with 
cytoplasmic vesicles in A-T cell lines [203, 204]. Two years later, another group 
demonstrated that the cytoplasmic fraction of ATM associates with peroxisomes and 
endosomes [205] and it is required for the functioning of these organelles. Moreover, the 
cytoplasmic fraction of ATM does not change in amount or in localization in response to 
IR [204, 206], meaning that the ATM cytoplasmic pool is distinct from the nuclear one 
and it is crucial for cellular and sub-cellular activities far from the function in genome 
surveillance. Importantly, in a pivotal study, Lim and colleagues demonstrated that 
cytoplasmic ATM binds β-adaptin, a member of the AP-2 adaptor complex, which is 
involved in clathrin-mediated endocytosis of receptors, membrane trafficking and cell 
signalling [207]. This interaction was demonstrated in vitro but also in vivo, by co-
immunoprecipitation and co-localization studies. The consequence of the interaction 
between ATM and β-adaptin is still unclear but indicates that cytoplasmic ATM may play 
an important role in intracellular vesicle and/or protein transport mechanisms. In fact, 
several ATM-related lipid kinases such as Vps34 and PI-3K are crucial in stimulating 
vesicles and protein transport [208]. This also allows to speculate that cytoplasmic ATM 
may act in vesicle transport and ATM deficiency could deeply impact on protein cellular 
homeostasis.  
In this contest, surprizing discoveries come from studies of cytoplasmic ATM in 
neurons. In literature, it is known that ATM is predominantly localized in the nucleus of 
dividing cells, while in post-mitotic cells like Purkinje and granular neurons in 
cerebellum, it has a significant distribution in the cytoplasm [203, 209]. This hypothesis 
has been confirmed by Karl Herrup’s group [210], which identified cytoplasmic ATM in 
neuronal cells from cortical structures but not in other peripheral tissue. They also 
discovered two novel binding partners of cytoplasmic ATM in cortical neurons: VAMP2 
and Synapsin-I, known synaptic vesicle proteins that localize in presynaptic nerve 
terminals. Synapsin-I is a linker protein that keeps synaptic vesicles (SV) related to the 
cytoskeleton, especially to actin, in presynaptic terminals [211]. Its function is crucial in 
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maintaining and stabilizing the reserve pool of SVs in the cytoplasm, near the plasma 
membrane, but also is essential to make SVs ready to be released. It prevents the diffusion 
and the random fusion of SVs upon repetitive synaptic activity and controls the 
availability of SVs for the release through its phosphorylation-dependent dissociation 
from SVs and actin. Thus, its main function is the homeostatic regulation of synaptic 
transmission [212]. Consistently, synapsin knockout studies have shown that synapsins 
are not required for neurite outgrowth, synaptogenesis or the basic mechanics of synaptic 
vesicle release, but they are essential for acceleration of synaptic vesicle trafficking 
during repetitive stimulation [213, 214]: a failure in synapsin function results in the 
defective short-term plasticity of synaptic transmission. Vesicle-Associated Membrane 
Protein2 (VAMP2; also known as Synaptobrevin2) instead, is a central member of the 
SNARE (soluble N ethylmaleimide-sensitive fusion protein-attachment protein receptor) 
complex that mediates synaptic vesicle fusion with the cell membrane allowing the 
neurotransmitter release [215]. The fusion of synaptic vesicles (SVs) with the pre-
synaptic plasma membrane is necessary for synaptic transmission at chemical synapses. 
This fusion event, termed exocytosis, occurs spontaneously at a low and asynchronous 
rate, whereas an increase in presynaptic Ca2+ mediates a larger and synchronous fusion 
of SVs with the plasma membrane [216, 217]. Crucial to SV exocytosis is the formation 
of a protein complex between SNARE proteins present on the plasma membrane and SV 
membrane [218].  In neurons, VAMP2 is a vesicle (or v) SNARE, whereas the plasma 
membrane proteins SNAP25 and Syntaxin1 act as target membrane (or t) SNAREs.  
These three SNARE proteins interact to form a trans SNARE complex which is thought 
to represent the minimal membrane fusion machinery [219]. Thus, VAMP2 is crucial in 
catalysing SVs fusion reactions and maintaining a proper rate of fusion activities during 
both spontaneous and evoked synaptic events. The interaction between ATM and these 
two presynaptic proteins suggests that cytoplasmic ATM might regulate synaptic 
transmission.  
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ATM controls E/I balance  
 
In line with the emerging roles of ATM in regulating neuronal functions, in last study 
published by our group, we unveiled a pivotal role of ATM in controlling the development 
of the inhibitory system and in maintaining a balanced E/I neuronal transmission at 
hippocampal level [220]. We demonstrated that hippocampal neurons obtained from Atm 
heterozygous (Het) mouse embryos display an E/I imbalance towards inhibition indicated 
by: i) a higher frequency of miniature inhibitory post synaptic currents (mIPSCs); ii) an 
increased number of inhibitory synapses. We revealed that this increased inhibitory tone 
is due to a precocious development of the GABAergic system, especially to an accelerated 
“excitatory-to-inhibitory switch of GABA”. As I largely described in Chapter 1, the 
development of GABAergic inhibition is associated to an excitatory to inhibitory shift of 
the action of GABA because of a reduction of [Cl-]i, induced by increased KCC2 
expression during development [43]. This phenomenon is fundamental for the 
development of the GABAergic network since it is widely accepted that it regulates the 
number and the strength of inhibitory synapses. In particular, a precocious GABA switch 
is known to increase GABAergic synapses and the frequency of GABAergic miniature 
postsynaptic currents [221, 222]. Thus, in Atm Het hippocampal cultures we showed by 
calcium imaging experiments, an accelerated switch of GABA related to a higher KCC2 
expression in hippocampal tissues obtained from Atm Het mice. We found that these 
rearrangements seem to depend to the higher activation of P-ERK and lower expression 
of its phosphatase, PP1, in Atm Het hippocampi [220]. We supposed that the increase of 
ERK activation could sustain the higher KCC2 expression since in literature is known the 
link between ERK phosphorylation and KCC2 expression through the Egr4-dependent 
activation of the Kcc2b promoter [50]. These data demonstrate that alterations of ATM 
expression at hippocampal level determine a precocious and sustained GABAergic 
development and function leading to an E/I imbalance in favour of inhibition. As I 
previously described, GABA transmission is strongly related to proper brain development 
and plasticity, thus this study adds a piece for a clearer comprehension of the molecular 
basis of brain development introducing ATM as a new key regulator. Moreover, this 
evidence provides a rationale for the cognitive deficits associated to milder form of A-T, 
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in which a residual amount of functional ATM is still present and introduces KCC2 and 
E/I balance as novel potential targets for emerging therapeutic approaches in AT.  
In accordance, Herrup and colleagues have recently deepened ATM function at the 
neuronal synapse. They discovered that ATM and its partner in DDR, ATR, contribute to 
the E/I balance by regulating synaptic vesicles recycling in cortical neurons [223]. They 
demonstrated that ATM and ATR specifically segregate to different classes of vesicles 
playing complementary roles: ATM with excitatory vesicles and ATR with inhibitory 
ones. They also demonstrated that the two proteins are in balance with each other, so a 
deficiency of ATM or ATR leads to a compensatory increased expression of the other 
kinase. This compensatory effect seems to occur rapidly and quickly influences the E/I 
balance [223].   
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Chapter 6 
 
Therapeutic relevance of ATM inhibition  
 
Since its central role in DNA damage response, ATM has become an attractive target 
for cancer therapy. Pre-clinical studies have encouraged the further clinical development 
of ATM inhibitors, both in combination with chemo- or radiotherapy, to sensitize cancer 
cells to DNA-damage-inducing agents and to promote apoptosis [224]. In addition, 
studies showing ATM involvement in insulin pathway, especially in the activation of Akt, 
have offered new perspectives for using ATM as therapeutic target for cancer treatment. 
In fact, the activation of Akt pathway is pivotal for cancer development and progression 
[202]. 
The emergence of new roles of ATM in controlling neuronal functions [210, 220, 
223] has expanded the prospect of using ATM inhibitors also in neurological disorders. 
Importantly, our recent finding of ATM role in controlling GABAergic development and 
in the maintenance of E/I balance lays the basis for a “drug-repositioning” of ATM 
inhibitors as a new tool in the treatment of neurodevelopmental disorders, a topic that I 
will discuss later in this thesis.  
 
 
ATM inhibitors: from early non-specific compounds to highly selective 
small molecules 
 
In parallel to the emerging role of ATM as a potential drug target especially for cancer 
therapy, in the last 15 years the development of ATM inhibitors has acquired more and 
more interest, passing from early non-specific compounds to highly selective inhibitors 
(Figure 11A-B). Historically, it has been reported that several methylxanthine-derived 
drugs (theophylline, pentoxifyllin and caffeine) can sensitize cells to radiations at low 
millimolar concentrations. The fungal metabolite wortmannin was the first compound 
proposed to target ATM [225]. It irreversibly inhibits several members of the PIKK 
family, including mTOR, DNAPKcs and ATM. However, the adverse side effects and 
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the high dosages (≥10 μM) necessary to obtain radiosensitizating effects, limited its 
utility. Caffeine is another molecule largely studied and used as radiosensitizing agent 
although its exact mechanism of action is still unclear [226]. It seems to act inhibiting the 
phosphotransferase activity of a protein kinase involved in checkpoint signalling of DNA 
damaged. Nevertheless, the required dose to inhibit ATM activity (IC50 of 0,2 mM) is 
close to its LD50 in vivo and too toxic to permit any use in animals. 
Considering that neither caffeine nor wortmannin are specific and potentially useful 
in vivo, new ATM inhibitors have emerged. High specificity and low dosage has been 
obtained through small molecules belonging to the “KU family”. KU analogues are 
pyranone compounds that can permeate through cell membranes and act as ATP-
competitive inhibitors of ATM with an IC50 ranging from 13 nmol/L to 3 nmol/L [227]. 
These small molecules are extremely selective for ATM, with at least a 100-fold 
differential in selectivity in a counter-screening against other members of the PIKK 
family.  
Inhibition of ATM kinase activity by KU results in a suppression of ionizing 
radiation-dependent phosphorylation of several ATM targets, such as p53, ƔH2AX, 
NBS1, and SMC1 [228, 229]. Consistently, cells exposed to KU display a significant 
sensitization to ionizing radiation-induced cytotoxicity and to the DNA double-strand 
break-inducing chemotherapeutic agents including etoposide and doxorubicin [230]. 
Following this discovery, a large number of studies tested KU effectiveness in 
radiosensitize different type of tumors such as gliomas [231], non-small cell lung cancer, 
bladder cancer [232], head and neck cancer [233]. In addition, it has been shown that KU 
suppresses cell proliferation and apoptosis by abolishing Akt activation in cancer with 
Akt dysregulated signaling [234].  
Nevertheless, KU compounds display a small tissue distribution due to a limited 
solubility. This represents a big problem especially for brain delivery since the inability 
to cross the brain-blood barrier [235]. To avoid these hitches several studies have been 
conducted looking for the better solution to increase KU therapeutic index and solubility 
in vivo. At this purpose, Batey and colleagues identified a novel ATM inhibitor belonging 
to “KU family”, KU-59403, which seems to have good tissue distribution, slow toxicity 
and significant chemosensitization in in vivo models of human cancer [236]. More 
recently, Wang group developed and evaluated nanoparticle formulations of KU. They 
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demonstrated that this approach is effective in vivo, using a mouse xenograft model of 
non-small cell lung cancer [237].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. A) Chemical structure of ATM inhibitors. B) Table showing principal properties of ATM 
inhibitors. Modified from Ronco, et al 2017.  
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AIM OF THE STUDY 
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Alterations in the balance between excitatory and inhibitory neurotransmission (E/I 
balance) have been largely described in neurological disorders such as epilepsy, autism 
and schizophrenia. E/I balance is mainly controlled by GABA, which through its 
inhibitory action operates as a brake for excitatory neurotransmission. A fundamental 
process in the maturation of GABAergic inhibition is the so called “excitatory-to-
inhibitory switch of GABA”, the postnatal transition of GABAergic transmission from 
excitatory to inhibitory. In this context we have recently unveiled a new role of ATM 
(Ataxia Telangiectasia Mutated) in controlling GABAergic development at hippocampal 
level. ATM is a large protein kinase, whose best-known function is associated to DNA 
damage response (DDR). Moreover, recent findings have highlighted its important role 
in neuronal survival and proliferation and in synaptic vesicles recycling. Thus, the 
absence of the protein may result in neuronal dysfunctions. Coherently, the 
neurodegenerative condition associated to genetic mutations in ATM gene, the Ataxia 
Telangiectasia (A-T), exhibits, besides cerebellar ataxia, a variable phenotype with 
cognitive impairment. Consistently, in our previous study, we demonstrated that 
hippocampal neurons with half amount of ATM protein (Atm heterozygous) display a 
precocious GABAergic development (i.e. excitatory to inhibitory GABA switch) and a 
higher inhibitory tone, both in vitro and in vivo, leading to an excitatory to inhibitory 
imbalance in favour of inhibition.  
Thus, starting from these premises, the aim of this thesis was to investigate the 
possibility to mimic, by a pharmacological intervention, the accelerated GABAergic 
development and potentiated inhibitory tone typical of the ATM heterozygous phenotype, 
to propose a new tool for the treatment of neurological disorders associated with 
developmental alterations and neuronal hyperexcitability. To address this issue, we 
exploited a potent and selective ATM inhibitor belonging to the “KU family”. We 
performed functional, biochemical and molecular analyses in order to investigate the 
effects of KU treatment on neuronal maturation and transmission both in vitro and in vivo. 
The data presented in this thesis clarify the central role of ATM in proper brain 
development and highlight ATM inhibition as a new potential pharmacological approach 
in the treatment of neurodevelopmental disorders.  
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EXPERIMENTAL PROCEDURES 
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Animals  
All the experimental procedures followed the guidelines established by the Italian 
Council on Animal Care and were approved by the Italian Government Decree No. 
27/2010 and the Italian Legislation (L.D. no 26/2014). All efforts were made to minimize 
the number of animals used and their sufferings. Wild type mice and transgenic mice for 
Atm and Mecp2 are under standard conditions of light and temperature, no more than 5 
per cage, with food and water ad libitum. 
 
Genotyping 
Genotyping for WT/Atm Het or KO and WT/Mecp2y/- animals was performed on tail 
extracted DNA, using polymerase chain reaction (PCR) technique. After DNA 
purification [238], 3 μl of DNA were added to: 7,5 μl of master mix (GoTaq Promega), 
0,25 µl of each Atm primer 50 μM, or 0,375 μl of each Mecp2 primer 20 μM and Nulcease 
free water to reach 12 µl of final volume. The DNA was amplified using thermocycler 
(Biorad, Hercules, CA, United States).   
Primers Sequences for Atm genotyping: 5’-TAGGGTGTAGTAGTGGAGGA-3’ as 
reverse primer, 5’-ACGTAAACTCGTCTTCAGACCT-3’ as forward primer for Atm 
null allele and 5’-GTAGTAACTATTAGTTTCGTGCA-3’ as forward primer for WT 
allele. Primers Sequences for Mecp2 genotyping: 5′-CCACCCTCCAGTTTGGTTTA-3′ 
as reverse primer, 5′-ACCTAGCCTGCCTGTACTTT-3′ as forward primer for Mecp2 
null allele and 5′-GACTGAAGTTACAGATGGTTGTG-3′ as forward primer for WT 
allele. 
 
Cell Cultures  
 
Characterization of KU impact on neuronal cultures was conducted on hippocampal 
neurons established from E18 rat littermates as previously described [19]. WT and Atm 
Het neuronal cultures were established from E18 mouse embryos; Mecp2y/- genetically-
modified mouse neurons were obtained from Postnatal day 0 (P0) pups to minimize the 
number of females sacrificed. Once obtained, hippocampi were chemically dissociated 
by treatment with 0.5% trypsin (Invitrogen) for 15 min at 37°C, followed by mechanical 
dissociation with a fire-polished Pasteur pipette. Dissociated cells were then plated on 
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poly-L-lysine-treated (1 mg/ml, Sigma-Aldrich) 24 mm glass coverslips in Neurobasal 
(Gibco) containing 2% B27 (Gibco), 1% Pen-Strep (Invitrogen), 0,5 mM glutamine, 12,5 
µM glutamate, as described in Brewer et al. [238], at densities ranging from 10x103 to 
20x103 cells/cm2. Neuronal cultures were kept at constant temperature (37°C) in the 
presence of 5% CO2. At 3 days in vitro (DIV), half of the culture medium was replaced 
with fresh medium without glutamate to avoid excitotoxicity phenomena.  
 
In vitro KU application 
 
The ATM inhibitor KU was dissolved in DMSO at the concentration of 10 mM and 
diluted in the neuronal medium at the final concentration 1 µM. For chronic treatment 
KU was applied for four consecutive days, from 8 to 11 days in vitro (DIV), without 
changing the medium. In the acute protocol neurons were treated at 5-6 DIV for 24 hours 
and functional properties were measured at 13-14 DIV.   
 
Immunocytochemistry  
 
Primary cortical cultures were fixed with 4% paraformaldehyde and 4% sucrose in 0,12 
M phosphate buffer for 20 minutes at 37°C and immunofluorescence staining was carried 
out as previously described [239]. Images were acquired using a Zeiss LSM 510 META 
confocal microscope with 60X objective. Immunofluorescence staining was carried out 
using the following antibodies: guinea pig anti-vGlut1 (1:1000), rabbit anti-vGAT 
(1:1000), both from Synaptic System, and mouse anti-βIII-tubulin (1:400) from Promega. 
Secondary antibodies were conjugated with Alexa-488, Alexa-555 or Alexa-633 
fluorophores (Invitrogen). The number of vGAT and vGlut1 positive puncta have been 
counted after the detection of an appropriate threshold which was set to 2.5-fold the level 
of background fluorescence referring to diffuse fluorescence within dendritic shafts. 
Fluorescence images processing and analyses were performed with ImageJ Software 
(National Institutes of Health). 
 
Calcium Imaging 
 
Hippocampal neurons were loaded with membrane-permeable fluorescent Ca2+ indicator 
Fura2-AM (Sigma-Aldrich) 1 μM for 30 minutes at 37 °C, then washed in [Krebs'-
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Ringer's-HEPES (KRH) in mM: 125 NaCl, 5 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2 CaCl2, 6 
glucose, and 25 HEPES-NaOH (pH 7.4)] and placed into the recording chamber of an 
inverted microscope (Axiovert 100, Zeiss) equipped with a calcium imaging unit in KRH 
and tetrodotoxin (TTX, Tocris) 1 µM. Fura2-AM was excited at 380 nm and at 340 nm 
through a Polychrom V (TILL Photonics GmbH) controlled by the TillVisION software 
4.01. Emitted light was acquired at 505 nm at a rate of 1–4 Hz and data collected with a 
CCD Imago-QE camera (TILL Photonics GmbH). Calcium transients (expressed as 
F340/380 fluorescence ratio) were calculated in discrete regions of interest (ROIs) of 
neuronal cell bodies and analysed along sequential images to follow temporal changes.  
For “GABA switch” experiments, after a period of baseline acquisition, neurons were 
stimulated with GABA 100 µM and increments in F340/380 ratio were considered only 
if higher than 0.05 units. After GABA administration neurons were washed with KRH, 
let recover few minutes and then excited with KCl 50 mM to identify vital neurons and 
to analysed Voltage Operated Calcium Channels (VOCC) expression. Transients smaller 
than 0.1 units were excluded from the analysis. 
 
Chloride Imaging  
6 DIV rat hippocampal neurons were loaded with 5 μM MQAE (Biotium) in KRH. 
MQAE is a 6-methoxyquinolinium derivative and it is used as a fluorescent indicator for 
intracellular chloride. This dye detects chloride via diffusion-limited collisional 
quenching. After 1-hour incubation at 37 °C, neurons were washed in KRH and 
transferred to the recording chamber of an inverted microscope (Olympus) equipped with 
a CellR imaging station. Image analysis was performed using Xcellence software 
(Olympus) measuring the mean fluorescence intensity of ROIs. 
 
In vitro electrophysiology 
Miniature excitatory and inhibitory post-synaptic currents (mEPSCs and mIPSCs) were 
recorded in the presence of TTX 1 µM; a reversible blocker of sodium channels that 
avoids the generation of action potentials. In presence of TTX the mPSCs incur 
spontaneously, induced by the release of a single vesicle. Thus, they correspond to the 
event generated from a quantum of neurotransmitter that interacts with postsynaptic 
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receptors. mEPSCs and mIPSCs were obtained from 13-14 DIV hippocampal neurons in 
whole cell patch clamp configuration using an Axopatch 200A amplifier (Axon 
Instruments, Forest City, CA, USA) in the voltage-clamp mode. Currents were sampled 
at 2 kHz and filtered at 2-5 kHz. External solution [Krebs'-Ringer's-HEPES (KRH)] had 
the following composition (in mM): 125 NaCl, 5 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2 
CaCl2, 6 glucose, and 25 HEPES-NaOH (pH 7.4). Recording pipettes were pulled from 
capillary glass (World Precision Instruments, Sarasota, FL, USA) using a two-stage puller 
(Narishige, London, United Kingdom) with tip resistances of 3-5 MΩ, and filled with 
intracellular solution (in mM): 130 Cs-Gluconate, 10 KCl, 1 EGTA, 10 HEPES, 2 MgCl2, 
4 MgATP and 0.3 Tris-GTP. Voltage-clamp recordings were performed at room 
temperature at holding potentials of -70 mV and +10 mV for mEPSCs and mIPSCs, 
respectively. Data were analysed off-line (pClamp10 software, Axon Instruments); 
mEPSCs had to exceed a threshold of -8 pA whereas mIPSCs of 6 pA. The I/E ratio has 
been calculated by dividing mIPSCs and mEPSCs frequencies measured in the same 
neuron. MultiUnit activity (MU) has been detected in cell-attached configuration 
clamping neurons at -60 mV and hyperexcitability was induced applying KRH without 
Mg++ as external solution during the entire recording session. Recording pipettes were 
filled with intracellular solution (in mM): 130 K-gluconate, 10 KCl, 1 EGTA, 10 HEPES, 
2 MgCl2, 4 MgATP and 0.3 Tris-GTP. 
 
Luciferase assay 
5 DIV hippocampal neurons were co-transfected with pNL1.1 [Nluc] vector (Promega) 
containing the -309/+42 region of the KCC2 mouse gene and pGL4.54 [luc2/TK] vector 
(Promega) using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
protocol. 2 days after transfection, cultures were briefly washed with PBS and lysed in 
Passive Lysis Buffer (Promega). Nluc and luc2 luciferase activities were aquired using 
Nano-Glo Dual-Luciferase Assay System (Promega).  
pNL1.1 [Nluc] vector was modified by introducing in its multiple cloning region the -
309/+42 region of KCC2 mouse gene containing specifically the Egr4 consensus 
sequence as unique binding site for transcription factors [50, 240]. Cloning procedures 
were performed by Bio-Fab Research srl (Rome). 
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Quantitative real time PCR 
6 DIV WT hippocampal neurons were treated with KU 1 µM and lysed prior to RNA 
extraction with TRIzol reagent (Invitrogen). Total RNA was extracted using the Direct-
zol RNA MiniPrep isolation kit (Zymo Research) according to the manufacturer’s 
protocol. The RNA was eluted with 25 μL DNase/RNAse-free water, measured using 
NANOdrop 2000c spectrophotometer (Thermo Fisher Scientific) and optical density 
260/280 nm ratios were calculated. Reverse transcription was performed using 1 μg RNA 
with a High Capacity cDNA RT kit (Applied Biosystems). Real-time polymerase chain 
reaction (qRT-PCR) was conducted using a CFX96 thermal cycler (Bio-rad) in a final 
volume of 10 μL with Sybr Green technique (SensiFAST SYBR Lo-ROX, Bioline). 
Mecp2 mRNA was analysed at least in duplicate and data analysis was performed with 
the ΔΔCt method and expressed as fold change. Mecp2 mRNA levels were normalized to 
Gapdh. 
 
In vivo KU injection   
Post-natal day 4 (P4) C57BL6/J WT pups were anesthetized by cold-ice procedure. After 
5 minutes animals received a single unilateral injection of 3 µL of KU 10 µM or DMSO 
in the lateral ventricle of the right hemisphere. 24 hours later, cortical and hippocampal 
tissues were explanted from both the ipsi- and contra-lateral hemispheres and stored at -
20° C for Western Blotting analysis or fixed of immunofluorescence. 
 
Immunohistochemistry  
 
24 hours after KU injection, pups were euthanized, and brains were explanted and fixed 
in 4% paraformaldehyde for 48 hours. Tissues were then included in 4% Low Melting 
Point agarose (Sigma-Aldrich) in 1X PBS. After agarose polymerization, sections of 50 
µm thickness were obtained using a VT1000S vibratome (Leica Microsystems). 
Immunofluorescence staining was carried out on free-floating dorsal hippocampus 
sections. Staining was performed using primary antibody against Mecp2 (Sigma-Aldrich) 
followed by incubation with a specific secondary antibody, counterstained with DAPI 
and mounted with Fluorsave (Merck). Images were acquired in the stratum radiatum of 
the CA1 subfield of the hippocampus using the x40 oil immersion objective with an 
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additional electronic zoom factor of up to 3 (voxel sizes of 0.10 × 0.10×1 μm) and 
maintaining the parameters of acquisition constant in each group.  
 
Western Blotting  
Proteins were obtained starting from explanted tissues homogenised in sample buffer 
(sodium dodecyl sulphate 1% (SDS), 62.5 mM Tris-HCl (pH 6.8), 290 mM sucrose); or 
from neurons scraped using a lysis buffer containing 3% SDS, 115 mM sucrose, 65mM 
Tris-HCl (pH 6.8), 0,1 % βmercaptoethanol. Protein content was assessed by 
bicinchoninic acid (BCA) assay, using BCA protein assay kit (Thermo Fischer 
Scientific). In this method, BCA molecules chelate cuprous ion Cu+, formed from Cu++ 
reduction by proteins in alkaline environment. This chelation generates a purple-coloured 
reaction product which has a strong absorbance at 562 nm, proportional to protein 
concentration in the sample. Sample absorbance was read through a spectrophotometer 
(Victor2 - 1420 multilabel counter, Wallac) set to 550 nm. Protein content was assessed 
through a bovine serum albumin-based standard curve. Protein were separated by SDS-
PAGE electrophoresis, blotted and incubated with primary antibody followed by HRP-
conjugated secondary antibody (Jackson ImmunoResearch) and developed by Pierce 
ECL Western Blotting Substrate (Thermo Fisher Scientific). The following primary 
antibodies were used: rabbit anti-KCC2 1:1000 (Millipore), rabbit anti-ATM 1:500 
(Millipore), rabbit anti-LC3B1/2 1:1000 (Cell Signaling), HSPA8 1:1000 (Cell 
Signaling), mouse anti-p-ERK 1:1000 (Sigma-Aldrich), rabbit anti-ERK1/2 1:1000 (Cell 
Signaling), rabbit anti-Mecp2 1:1000 (Sigma-Aldrich) antibodies. Rabbit anti-calnexin 
1:1000 (Sigma-Aldrich), mouse anti-actin 1:1000 (Sigma-Aldrich) or mouse anti- βIII 
tubulin (Sigma-Aldrich) were used to normalize. 
 
Statistics 
Pairwise comparisons between treatments were assessed with Student’s t-test. One-way 
ANOVA with repeated measures or 2-way ANOVA as between subject factor were used. 
Post hoc analysis was done using Tukey’s, Bonferroni’s or Holm Sidak’s post hoc tests. 
The differences were considered significant, if p<0.05 (indicated by one asterisk), p<0.01 
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(double asterisks), p<0.005 (triple asterisks). All statistical analyses were done with 
software Prism, version 6 (GraphPad). 
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RESULTS 
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Characterization of the ATM kinase inhibitor KU in 
neuronal primary cultures 
 
KU effectiveness and duration of action  
 
In order to investigate how and at which extent the pharmacological blockade of 
ATM kinase activity could impact hippocampal function, we exploited a potent and 
selective ATM inhibitor belonging to the “KU family”. As I largely described before, KU 
molecules are small compounds that can permeate through cell membranes and act as 
ATP-competitive inhibitors of ATM. Until now, these molecules have been largely 
studied in the oncological field, since it has been demonstrated that ATM inhibition 
induces cancer cells apoptosis and sensitizes cells to ionizing radiation (IR), improving 
efficacy of IR therapy in several types of cancer [228-230]. First, we evaluated KU 
effectiveness and duration of action in hippocampal primary cultures established from rat 
embryos. To test whether KU is able to penetrate inside neurons efficiently and then 
inhibits the kinase activity of ATM, 14 DIV (days in vitro) cultured hippocampal neurons 
were treated for an hour with 20 µM of Etoposide (ETO), to elicit the ATM dependent 
DNA damage response [241], or 20 µM of Etoposide plus 10 µM of KU. Then, the 
experimental groups were analysed by Western Blotting experiments to quantify the 
extent of ATM phosphorylation using the specific antibodies against ATM total protein 
and P-ATM S1981. While Etoposide treatment clearly activates ATM kinase activity, as 
showed by the appearance of the phosphorylated form of ATM (P-ATM in red, Figure 
1A) compared to control (first band, Figure 1A), KU 10 µM co-application clearly 
abolishes this activation (third band, Figure 1A). To assess the duration of action of KU 
in hippocampal neuronal cultures, we carried out Western Blotting analysis. We therefore 
treated 14 DIV cells with KU 10 µM and we collected samples at different time points: 4 
hours, 24 hours or 48 hours after KU application. In all the experimental conditions 
Etoposide was applied an hour before cell lysis. Western Blotting analyses revealed that 
KU activity persists up to 24 hours after treatment, then decreases and disappears 48 hours 
later, when P-ATM/ATM ratio is comparable to Etoposide experimental condition 
(Figure 1B).  
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Setting-up KU concentration in neurons  
 
After establishing KU effectiveness and duration of action, we treated neurons with 
different KU concentrations (1 µM, 5 µM and 10 µM) and both in acute (4 hours) and 
chronic (4 days) paradigms, in order to individuate the lower dose able to produce the 
desired effects without affecting neuronal health. Firstly, we performed 
immunofluorescence experiments on 12 DIV hippocampal primary cultures labelling 
neurons with βIII-tubulin to better see the morphology and the branching of neuronal 
processes. As indicated by qualitative immunofluorescence images, the acute treatment 
(4 hours) with KU 5 µM and 10 µM induces neuronal damage determining the appearance 
of varicosities along tubulin-labelled neuronal processes (Figure 2). The formation of that 
kind of varicosities has been already described by Borghesani and colleagues, as a first 
sign of neurodegeneration in ATM-deficient Purkinje cells [149]. Coherently, the chronic 
treatment (4 days) with KU 5 µM produces neuronal varicosities and deeply affects 
neuronal survival as indicated by the strong reduction of dendritic arborisations (Figure 
Figure 1. (A) Representative image and analysed data of Western Blotting experiments carried-out on 14 
DIV rat hippocampal neurons treated with Etoposide (ETO) 20 µM or ETO plus the ATM inhibitor KU 10 
µM. (B) Western Blotting analysis of KU duration of action in 14 DIV hippocampal neurons.  
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2). On the other hand, both the acute and the chronic administration of KU 1 µM keeps 
neuronal processes healthy (Figure 2).  
 
 
 
 
 
 
 
 
To better investigate the impact of KU chronic treatment on neuronal function and 
homeostasis, we performed calcium imaging experiments on primary neuronal culture 
exposed to KU 5 µM or 1 µM for 4 days (from 8 to 12 DIV) and loaded with the 
ratiometric calcium indicator Fura-2AM. Calcium imaging data revealed alterations in 
neuronal calcium homeostasis after KU 5 µM chronic treatment, indicated by a higher 
F340/380 fluorescence ratio, confirming that concentrations higher than 1 µM result in 
neuronal damage and functional impairments (Figure 3A). We also checked for any 
possible unspecific effect linked to the use of KU 1 µM, but we did not find changes in 
both intracellular basal calcium levels (Figure 3A) and in the expression of Voltage 
Operated Calcium Channel (VOCC), as indicated by comparable intracellular calcium 
increases upon KCl stimulation (Figure 3B). Moreover, several studies show that KU 
concentrations even higher than 1 µM display a good selectivity for ATM kinase [242-
244]. Thus, we established 1 µM as the ideal KU concentration able to guarantee both 
safety, selectivity and effectiveness in neuronal primary cultures. 
Figure 2. Representative immunofluorescence images of 12 DIV rat hippocampal neurons labelled with a 
specific antibody against βIII-tubulin display the occurrence of pathological varicosities along neuronal 
processes upon both chronic and acute treatments with KU 5 µM and 10 µM. Only KU 1µM - treated cells 
appear healthy.  
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Figure 3. Calcium imaging experiments conducted on rat hippocampal neurons chronically treated with 
KU 1 µM or 5 µM from 8 to 12 DIV. A) Quantitative analysis of basal calcium levels. Neurons exposed to 
the chronic treatment with KU 5 µM display increased resting calcium levels compared to control (Kruskal-
Wallis Test followed by Dunn’s Multiple Comparison Test, **p<0,01. CTRL n=244; KU 1µM n=221; KU 
5µM n=200). B) Calcium transients evoked by KCl 50mM application in neurons chronically treated with 
KU 1µM vs controls (Mann-Whitney Test, p=0,214. CTRL n=244; KU 1µM n=219). 
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Evaluation of functional changes induced by KU 
treatment in neurons  
 
Neuronal exposure to KU enhances inhibitory neurotransmission and 
KCC2 expression  
 
Our next goal was to investigate the possible occurrence of changes in basal synaptic 
transmission after the pharmacological blockade of ATM kinase activity through KU. At 
this purpose, we daily treated hippocampal neurons from 8 to 11 days in vitro (DIV) with 
KU 1 µM and we performed electrophysiological recordings of excitatory and inhibitory 
miniature post-synaptic currents at 12 DIV (Figure 4A). Miniature excitatory and 
inhibitory post-synaptic currents (mEPSCs and mIPSCs) (Figure 4B), or MINIs, were 
recorded in whole-cell voltage clamp in the presence of 1 µM tetrodotoxin TTX (Tocris). 
TTX is a reversible blocker of sodium channels, that avoids the generation of Action 
Potentials. In fact, the mPSCs are calcium independent-events which incur 
spontaneously, induced by the release of a single synaptic vesicle, thus they correspond 
to the release of “a quantum” of neurotransmitter that interacts with postsynaptic 
receptors [245]. This analysis allows to specifically measure functional synaptic 
properties. In particular, the frequency of mPSCs, measured in Hertz (Hz), indicates the 
number of mPSCs per second and is a parameter strictly related to the pre-synaptic 
compartment since it is influenced by the number of synaptic vesicles contained in each 
pre-synapsis, the probability of vesicle release and the number of pre-synaptic 
compartments that approach the patched neuron. On the other hand, the amplitude of the 
mPSCs is a measurement of post-synaptic properties, since it directly depends on the 
number of functional post-synaptic receptors expressed along the membrane [246, 247]. 
Electrophysiological data showed that the chronic treatment with KU 1 µM potentiates 
inhibitory synaptic transmission in terms of mIPSCs frequency (Figure 4C left) but not 
of amplitude (Figure 4E), indicating a prevalent pre-synaptic effect. Conversely, the 
excitatory counterpart remains unaffected (Figure 4C right – Figure 4F), leading to an 
excitatory/inhibitory imbalance in favour of inhibition (Figure 4D).  
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Figure 4. A) Scheme showing the temporal line of KU chronic treatment in hippocampal cultured neurons. 
B) Representative electrophysiological traces of inhibitory and excitatory miniature post-synaptic currents 
(mIPSCs and mEPSCs) measured in 12 DIV neurons chronically treated with KU. C) Electrophysiological 
analysis of mIPSCs and mEPSCs frequency (mIPSCs: Mann-Whitney Test, **p=0,005; CTRL n=20; KU 
n=26. mEPSCs: Mann-Whitney Test, p=0,247. CTRL n=21; KU=25). D) Quantification of 
excitatory/inhibitory ratio (E/I ratio) evaluated by measuring the frequency of excitatory and inhibitory 
events from each single cell in whole-cell configuration (Mann-Whitney Test, *p=0,027. CTRL n=14; KU 
n=20). E-F) Analysis of mIPSCs and mEPSCs amplitude plotted as cumulative probability (mIPSCs: KS 
test, p=0,073. CTRL n (events)=818; KU n (events)=1809. mEPSCs: KS test, p=0,128. CTRL n 
(events)=1480; KU n (events)=1233).   
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Since in our previous study we demonstrated a potentiated inhibitory tone probably 
linked to an increased KCC2 expression and precocious GABAergic development in Atm 
heterozygous (Het) hippocampal neurons [220], we investigated the hypothesis that the 
enhanced mIPSCs frequency, induced by the pharmacological blockade of ATM activity 
through KU, could be ascribed to increased KCC2 levels. To address this issue, we first 
confirmed the direct link between “ATM kinase activity - KCC2 levels and degree of 
GABAergic inhibition”, taking advantages of the specific KCC2 receptor antagonist, 
VU0240551 (VU) [248, 249]. The exposure of wild type neurons to VU 1 µM determines 
a significant intracellular chloride accumulation, measured with the chloride fluorescent 
indicator MQAE, proving VU effectiveness in blocking KCC2 action (Figure 5A). We 
therefore treated Atm Het neurons, which exhibit higher levels of KCC2, with VU 1 µM 
during development, and we assessed VU rescuing of functional deficits in Het compared 
to controls. At this purpose, we evaluated the excitatory-to-inhibitory switch of GABA 
through calcium imaging experiments, as an index of GABAergic development strictly 
related to KCC2 expression [44], and the E/I balance by electrophysiological recordings 
(Figure 5B). Calcium imaging experiments, performed in 5 DIV neurons loaded with the 
ratiometric calcium indicator Fura-2AM, revealed that VU treatment is effective in 
normalizing the anticipated inhibitory action of GABA typical of Atm Het cells, as 
indicated by a comparable percentage of neurons responding to GABA 100 µM stimuli 
with calcium transients in wild-type (WT) vs Het+VU experimental conditions (Figure 
5C). In addition, we did not find any changes in calcium homeostasis after VU 
administration, as showed by the undistinguishable calcium basal levels measured in Het 
treated cells compared to WT (Figure 5D). Only weak alterations in calcium homeostasis 
have been detected in WT neurons upon VU treatment accordingly to Sivakumaran et al, 
2015 [250] (Figure 5D). Also, electrophysiological recordings of mEPSCs and mIPSCs 
from each single cell performed in 14 DIV neurons showed the effectiveness of VU 
treatment during development in rescuing the increased inhibitory tone, indicated by a 
normalized mIPSCs frequency (Figure 5E), and the imbalanced E/I transmission (Figure 
5F). All together these data provide the unequivocal proof of the direct link between ATM 
activity, KCC2 levels and degree of inhibition.  
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Figure 5. A) Intracellular chloride measurements in 6 DIV primary hippocampal neurons upon 
VU0240551 (VU) treatment. Quantitative analysis of the MQAE mean intensity: a lower MQAE mean 
intensity in VU-treated cultures indicates an increased [Cl-]I (Student’s t-test, ***p<0,001. CTRL n=138; 
VU n=133). B) Scheme of the experimental time line of VU treatment and related functional experiments. 
C) Quantitative analysis of the percentage of 5 DIV Atm Het/WT neurons, treated or not with VU, 
responding to GABA application by depolarization (Kruskal-Wallis Test followed by Dunn’s Multiple 
Comparison Test, **p<0,01. WT n=362; WT+VU=214; Het=342; Het+VU=299). D) Evaluation of 
resting calcium level in Atm Het/WT cells upon VU treatment (Kruskal-Wallis Test followed by Dunn’s 
Multiple Comparison Test, *p<0,05. WT n=362; WT+VU=214; Het=342; Het+VU=299). E) 
Electrophysiological analysis of mIPSCs frequency in 14 DIV Atm Het/WT hippocampal neurons treated 
or not with VU (Kruskal-Wallis Test followed by Dunn’s Multiple Comparison Test, *p<0,05 - **p<0,01. 
WT n=16; WT+VU n=13; Het n=14; Het+VU=15). F) Quantification of E/I ratio in 14 DIV Atm Het/WT 
hippocampal neurons upon VU chronic treatment (One-way Anova followed by Holm-Sidak’s Multiple 
Comparison Test, *p<0,05. WT n=15; WT+VU n=11; Het n=11; Het+VU=11). 
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To investigate if KU effects on GABAergic transmission are due to changes in KCC2 
expression, we performed Western Blotting experiments of chronically treated neurons, 
but we did not observe any statistical significant increase in KCC2 levels (Figure 6A). 
Moreover, we did not find significant changes in KCC2 expression also in 12 DIV 
neurons treated for 1 hour or 24 hours with KU (Figure 6A). So, we hypothesized that we 
were not in the proper time window to see possible alterations in KCC2 levels since it is 
well known that at this developmental stage (12 DIV) KCC2 reaches a saturating 
expression level and GABA switch is almost completed [43, 251]. Thus, we moved earlier 
during development and we treated cells at 7 DIV, since it is well described that in this 
phase of neuronal maturation about 40-50% of neurons still respond to GABA with 
depolarizing calcium transients [181]. We found that at this time point the acute KU 
application (for 30 or 60 minutes) is sufficient to induce a strong increase of KCC2 
expression (Figure 6B) associated with a higher phosphorylation of ERK1/2 (Figure 6C). 
These results suggest that the functional modifications obtained through the chronic 
protocol could be ascribed to a precocious and transient increment of KCC2.  
 
 
Figure 6. Evaluation of KCC2 protein level upon different KU treatment paradigms. A) Western Blotting 
representative image and quantification of KCC2 expression in 12 DIV neurons treated with KU 1 µM for 
4 days, 24 hours or 60 minutes, showing no differences between the experimental groups (Kruskal-Wallis 
Test followed by Dunn’s Multiple Comparison Test, p=0,075. CTRL n=8, 4days n=6; 24h n=5; 60’ n=2). 
B) Representative Western Blotting lanes and analysis of KCC2 levels upon KU acute treatment (30-60 
minutes) in 7 DIV hippocampal cultures (One-way Anova followed by Holm-Sidak’s Multiple Comparison 
Test, **p<0,01. CTRL n=7; 30’ n=7; 60’ n=7). C) Biochemical analysis of the amount of ERK 
phosphorylation in acutely KU-treated 7 DIV neurons compared to control (Kruskal-Wallis Test followed 
by Dunn’s Multiple Comparison Test, *p<0,05 - **p<0,01. CTRL n=7; 30’ n=7; 60’ n=6). 
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KU treatment promotes GABAergic development and reverts the E/I 
balance  
 
Since Western Blotting data revealed that KU effects on KCC2 expression occur 
strictly during the early phases of neuronal development, we decided to modify our 
protocol treating neurons for one day at 5/6 DIV and to evaluate possible changes in the 
“excitatory-to-inhibitory switch of GABA” as a consequence of increased KCC2 levels 
(Figure 7A). Calcium imaging experiments performed in Fura-2AM loaded neurons 
showed that KU application for 24 hours accelerates GABAergic maturation, as indicated 
by a reduced percentage of cells responding to GABA with calcium transients (Figure 
7B), suggesting an anticipated GABA-mediated hyperpolarizing action upon KU 
treatment. Surprisingly, we found that this effect is long-lasting, since even four days after 
KU application the excitatory-to-inhibitory switch of GABA remains accelerated with a 
reduced percentage of neurons responding to GABA stimuli by depolarization compared 
to control (Figure 7C). We also measured calcium transients evoked by KCl 50 mM 
application, in order to exclude the occurrence of possible changes in Voltage Operated 
Calcium Channels (VOCCs) expression and function upon KU delivery, but we did not 
find any changes between the two groups (Figure 7D). The evaluation of VOCCs in these 
kind of experiments is fundamental since their alterations could reflect variations in 
neuronal responses to GABA and, as a result, an altered estimation of the percentage of 
GABA responding neurons. Interestingly, Western Blotting data revealed increased 
KCC2 levels only one day but not 4 days after KU application (Figure 7E), suggesting 
that the acute boosting of KCC2 expression is sufficient to produce a long-lasting effect 
on GABA maturation.  
To further demonstrate that the KU long-lasting effect on GABAergic development 
is exclusively determined by the acute boosting of KCC2 expression, we treated 6 DIV 
neurons with KU 1 µM for 24 hours, we co-applied VU 1 µM at 6 DIV and we continued 
VU application for the following two days (7-8 DIV) (Figure 7F above). VU inhibition 
of KCC2 activity blocks the KU-mediated long-lasting effect on GABA switch as 
indicated in (Figure 7F bottom).  
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Figure 7.  A) Scheme of the experimental design for the evaluation of KU acute treatment induced effects 
on GABA switch. B-C) Quantification of the percentage of 6 DIV hippocampal neurons responding to 
GABA stimuli by depolarization one day (B) and four days (C) after KU 1 µM application with respect to 
controls (one-day treatment: Student’s t-test, **p=0,004. CTRL n=395; KU=374. Four-days treatment: 
Student’s t-test, *p=0,039. CTRL n=216; KU n=236). D) Analysis of calcium transients upon KCl 50 mM 
application in one day (left) and four days (right) treated-cells compared to controls display no changes in 
VOCC expression in all the experimental conditions (one-day treatment: Mann-Whitney Test, p=0.145. 
CTRL n=395; KU=374. Four-days treatment: Mann-Whitney test, p=0.777. CTRL n=216; KU n=236). E) 
Representative Western Blotting lanes and corresponding quantifications of KCC2 expression levels one 
day and four days after KU treatment (one-day treatment: Mann-Whitney Test, **p=0,005. CTRL n=7; 
KU n=11. Four-days treatment: Mann-Whitney test, p=0,918. CTRL n=7; KU n=11). F) Scheme showing 
the temporal line of KU and VU co-application experiment (above). Analysis of the excitatory-to-inhibitory 
switch of GABA reveals that VU administration prevents KU effects on GABAergic maturation (bottom) 
(Kruskal-Wallis Test followed by Dunn’s Multiple Comparison Test, *p<0,05. CTRL n=204; KU n=163; 
KU+VU n=334).  
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Our next goal was to investigate if the accelerated and potentiated GABAergic 
development induced by one-day treatment with KU could induce permanent changes of 
neuronal transmission. We therefore treated cells at 5/6 DIV and we measured excitatory 
and inhibitory synaptic activity in mature neurons (14 DIV) taking advantages of 
electrophysiological experiments (Figure 8A). Electrophysiological recordings revealed 
an increased inhibitory tone upon KU application, as indicated by the higher frequency 
(Figure 8B - 8C left) and amplitude (Figure 8E) of mIPSCs. The excitatory counterpart 
results instead decreased both in term of frequency (Figure 8B - 8C right) and amplitude 
(Figure 8F) of mEPSCs, leading to an E/I imbalance in favour of inhibition (Figure 8D). 
Accordingly, immunofluorescence analysis revealed increased mean size and mean 
intensity of vGAT-positive puncta (Figure 9A-B-C) and a reduction in these parameters 
in vGlut-positive puncta (Figure 9A-D-E).  
These data suggest that KU acute application during development exerts long-lasting 
effects on synaptic transmission completely reverting the E/I balance in mature neurons. 
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Figure 8. A) Experimental time–line to measure changes in synaptic transmission upon KU acute treatment 
during development. B) Representative traces of mIPSCs and mEPSCs recorded in 14 DIV hippocampal 
neurons treated or not with KU 1 µM during development. C) Quantitative analysis of mIPSCs (left) and 
mEPSCs (right) frequency in KU-treated cells compared to control (mIPSCs: Student’s t-test, 
***p=0,0003. CTRL n=17; KU n=19. mEPSCs: Student’s t-test, *p=0,026. CTRL n=21; KU=17). D) 
Electrophysiological quantification of the E/I ratio upon KU acute treatment (Student’s t-test, **p=0,002. 
CTRL n=14; KU n=13). E-F) Analysis of mIPSCs and mEPSCs amplitude plotted as cumulative 
probability (mIPSCs: KS test, p<0,0001. CTRL n (events)=773; KU n (events)=823. mEPSCs: KS test, 
p<0,0001. CTRL n (events)=1378; KU n (events)=1037).   
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Figure 9. A) Representative immunofluorescence images of 14 DIV hippocampal neurons labelled with the 
specific inhibitory and excitatory pre-synaptic markers, respectively vGAT and vGlut1, and with βIII-
tubulin to highlight neuronal processes. B-C) Quantitative analysis of mean size (B) and mean intensity 
(C) of vGAT positive puncta in KU-treated neurons with respect to controls (mean size: Student’s t-test 
**p= 0,004. Mean intensity:  Student’s t-test, *p=0,040. N=3 experiments, n=2 coverslips for each 
experiment). D-E) Quantitative analysis of mean size (D) and mean intensity (E) of vGlut positive puncta 
in KU-treated neurons vs controls (mean size: Student’s t-test *p= 0,026. Mean intensity:  Student’s t-test, 
*p=0,021. N=3 experiments, n=2 coverslips for each experiment). 
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KU counteracts the hyperexcitability induced in neurons  
 
Whereas our ultimate goal in the study of KU effects is to exploit it as a new 
pharmacological tool in the treatment of disorders characterized by increased excitation 
and altered GABA maturation, we evaluated the possibility that the higher inhibition 
induced by KU treatment could counteract hyperexcitability of neuronal networks. To 
address this issue, we focused on hyperactivity processes acutely generated in vitro by 
exposing neurons to a Mg2+ free external medium [252, 253]. The Mg2+ removal indeed 
determines the unblock of NMDA glutamatergic receptors, which are normally silent at 
resting potential, since magnesium ions occupy the binding site deep inside the pore near 
the cytoplasmic side of the channel [254]. We therefore acutely treated cells with KU 
during development and we performed electrophysiological experiments at 14 DIV. We 
measured Multi Unit (MU) activity recording neurons in voltage-clamp mode and in cell 
attached configuration [255]. The analysis of this parameter allows to monitor the spiking 
activity of the recorded neuron as well as of its immediate neighbours and it is known to 
reflect the excitability of neuronal network [255].  As shown in Figure 10A-B, while the 
MU number was significantly increased in neurons exposed to the Mg2+-free protocol 
with respect to controls (KRH), no statistically significant increment in MU frequency 
was observed after Mg2+ removal upon KU treatment. These data suggest that the higher 
GABAergic tone induced by KU is effective in counteracting the pharmacologically-
mediated hyperexcitability and highlight KU as a new tool potentially exploitable in 
reverting pathological features of neurodevelopmental disorders characterized by 
increased excitation and/or reduced inhibition. 
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Figure 10. A) Representative electrophysiological traces of Multi-Unit (MU) activity (i.e. spiking activity) 
recorded in voltage-clamp in cell attached configuration in 14 DIV hippocampal cultured neurons, treated 
or not with KU during development, before and after the Mg2+ removal from the external solution. B) 
Quantitative analysis of MU frequency reveals potentiated activity in control cultures but not in KU treated 
cells during development, after the application of the hyperexcitability paradigm (One-Way Anova followed 
by Holm-Sidak’s Multiple Comparison Test: ***p<0,001 - **p<0,01. CTRL n=34; CTRL w/o Mg2+ n=28; 
KU n=21; KU w/o Mg 2+ n=27).  
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Assessment of the possible molecular mechanisms 
underlying KU effects 
 
KU is effective in enhancing KCC2 levels even in vivo 
 
To further demonstrate the pharmacological applicability of KU in neurological 
disorders, we investigated KU effectiveness in vivo. To this purpose, we performed 
intracerebroventricular injections (ICV) of 3 µl of KU 10 µM in the right ventricle of 
post-natal day 4 (P4) wild-type mice and we quantified KCC2 expression 24 hours later. 
We chose this administration paradigm since KU displays a very limited solubility and it 
is not able to cross the blood-brain barrier [235]. Western Blotting data showed a higher 
expression of KCC2 in brains of KU-treated mice compared to controls (DMSO-injected 
mice), indicating KU effectiveness also in vivo (Figure 11).  
 
 
 
 
 
 
Since in literature it is known that the concentration of KU 2 µM can inhibit 
autophagosome formation in vitro [243], we evaluated the impact of our treatment (KU 
10 µM - ICV) on basal autophagy in vivo. This is an extremely important point 
Figure 11. A-B) Representative Western Blotting lanes and quantitative analysis of KCC2 expression 
levels measured in P5 wild-type mice 24 hours after a single intracerebroventricular injections of KU 
10µM (3 µl) in the right ventricle (Mann-Whitney Test, p=0,0008. Number of animals=12 per group).  
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considering that autophagy processes are crucial during neurodevelopment, especially for 
the formation of correct synaptic contacts, and their dysregulation plays a crucial role in 
neurological disorders [8, 256, 257]. To address this issue, we measured the expression 
levels of a pivotal marker of autophagy, the microtubule-associated protein 1 light chain 
3 BII isoform (LC3-BII) [258, 259], in tissues explanted from KU-injected pups. As 
shown in Figure 11A-B, one day after KU in vivo administration, LC3-BII expression 
remains unaffected. We also evaluated Heat Shock Protein Family A (Hsp70) Member 8 
(HSPA8) levels since it is an ubiquitous molecular chaperone known to play an important 
role in protein folding and degradation, stress response, endosomal micro-autophagy, and 
chaperone-mediated autophagy [260, 261]. However, we did not find any changes after 
KU application Figure 11A-C. Thus, in our experimental conditions, KU does not seem 
to impact autophagy pathways.  
 
 
 
 
 
 
Figure 12. A) Representative Western Blotting lanes of the autophagy marker LC3B-II, the endosomal 
micro-autophagy and chaperone-mediated autophagy marker HSP8A, and the house-keeping protein actin. 
B-C) Quantitative analyses of LC3B-II (B) and HSPA8 (C) expression in KU-injected P5 pups’ brains with 
respect to controls (LC3B-II: Student’s t-test, p=0,237. HSPA8: Student’s t-test, p=0,642. Number of 
animals=12 per group).  
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KU promotes KCC2 expression through Egr4 activation of Kcc2b promoter  
 
We then wanted to define the molecular mechanisms responsible of KU effects. In 
literature is known that KCC2 expression during development is tightly regulated by Egr4 
transcription factor which, once activated by ERK protein, promotes the transcription of 
Kcc2 gene (Figure 13A) [50, 262].  In our previous study we found increased KCC2 levels 
correlated to a higher ERK phosphorylation in Atm Het mice [220], so we hypothesized a 
possible involvement of Egr4 pathway in ATM regulation of KCC2 expression. To better 
investigate this hypothesis, we took advantage of a construct including the -309/+42 
region of the Kcc2b mouse promoter, which contains exclusively the Egr4 consensus 
sequence [262], followed by the NanoLuc luciferase gene reporter. Thus, we transfected 
5 DIV neurons with the construct, we applied KU 24 hours later (6 DIV), and we 
measured the NanoLuc and Luc2 luciferase activity by a Dual-Luciferase Reporter Assay 
System one day after KU application (7 DIV). As shown in Figure 13B, we measured an 
increased NanoLuc/Luc2 signal in KU treated cultures compared to control, indicating 
that ATM involvement in GABAergic development is linked to a transcriptional 
mechanism involving the Egr4-dependent activation of Kcc2b promoter.  
 
 
 
Figure 13. A) Simplified schematic diagram of the signal transduction cascade involved in Egr4-induced 
KCC2 expression. Modified from Ludwig, et al 2001. B) Scheme of the transfected construct to evaluate 
Egr4 activity on Kcc2b promoter through Luciferase assay (above). Quantitative analysis of NanoLuc/Luc2 
luciferase activity in 7 DIV transfected cells upon KU application for one day (Student’s t-test, *p=0,019. 
CTRL n=5; KU n=8) (below).  
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Coherently, a significantly higher Egr4-dependent activity of Kcc2b promoter was 
found in Atm Het neurons (7 DIV) respect to WT (Figure 14A), indicating Egr4 pathway 
implication also in the genetic reduction of ATM. Surprisingly, Atm knockout (KO) 
neurons display a lower Egr4 activity respect to WT even in presence of an increased 
KCC2 expression in hippocampal tissues (Figure 14B). These results indicate the 
presence of an additional mechanism linked to ATM that converge in a potentiated KCC2 
expression. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. A) Luciferase quantitative analysis of Egr4 activity on Kcc2b promoter in 7 DIV hippocampal 
neurons obtained from Atm WT/Het/KO embryos (One-Way Anova followed by Dunnett’s Multiple 
Comparisons Test, *p<0,05. WT n=6, Het n=7, KO n=7). B) Western Blotting representative image and 
quantification of KCC2 expression levels in Atm KO hippocampi with respect to WT (Student’s t-test, 
*p=0,032. WT n=4; KO n=4).  
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KU enhances Mecp2 transcription  
 
To define the mechanism responsible for the increased KCC2 expression in Atm KO 
mice, we wondered if other transcriptional pathways could operate in parallel and 
independently to Egr4. Several studies point out the direct regulation of KCC2 expression 
via Methyl-CpG-binding protein 2 (MeCP2) activity both in human and in mice [60, 69, 
74]. Notably, it has been demonstrated that Mecp2, occupying the repressor element-1 
(RE-1) sites in the Kcc2 gene, prevents REST binding and so the inhibition of KCC2 
expression [60]. Thus, we evaluated Mecp2 levels in both genetic and pharmacological 
mouse models of ATM depletion. Surprisingly, Western Blotting data revealed higher 
levels of Mecp2 not only in hippocampal tissues extracted from Atm KO mice (Figure 
15A) but also in Atm Het and in KU-injected (3 L of KU 10 M) mice with respect to 
controls (Figure 15B-C).  
 
 
 
 
Figure 15. Representative images and corresponding analyses of Mecp2 expression in brains of both 
genetic and pharmacological mouse models of Atm depletion. A) Mecp2 increased level in Atm KO 
hippocampi compared to WT (Student’s t-test, **p=0,006. WT n=4; KO n=5). B) Mecp2 increment in Atm 
Het hippocampi respect to the WT counterpart (Student’s t-test, *p=0,040. WT n=5; Het n=10). C) P5 KU-
injected pups’ brains display higher Mecp2 expression compared to DMSO controls (Student’s t-test, 
*p=0,011. DMSO n=14; KU n=15).  
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In parallel, immunofluorescence experiments carried out on hippocampal slices 
confirmed increased Mecp2 expression after KU ICV injection, as indicated by confocal 
analysis of Mecp2 integrated density (Figure 16A-B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. A) Representative confocal immunofluorescence images of hippocampal slices obtained from 
KU-injected mice scarified 24h after KU injection, labelled with Mecp2 antibody (green) and DAPI (blue) 
to identify the nuclei. B) Quantification of integrated density of fluorescence for Mecp2 signal in DAPI 
positive nuclei plotted in column graph (above) and as relative frequency percentage (below) (Mann-
Whitney Test, ***p<0,001. KS test: ***p<0,001. Number of animals: DMSO=4 vs KU=4; number of 
slices: DMSO=12 vs KU=12; number of images quantified per slices=6).  
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As shown in Figure 17, qRT-PCR analysis of Mecp2-mRNA levels revealed that 
Mecp2 transcription is transiently potentiated 30 and 60 minutes after KU application, 
suggesting that ATM activity impacts Mecp2 expression at transcriptional level. All 
together these results demonstrate that KCC2 expression is finely modulated by ATM 
kinase activity through Egr4 and Mecp2 pathways which occur independently. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Quantification of Mecp2 mRNA levels by real time PCR experiments in hippocampal cultured 
neurons treated with KU or DMSO as control for different duration (Kruskal-Wallis followed by Dunn’s 
Multiple Comparisons Test: ***p<0,001 - *p<0,05. CTRL n=7; KU 30 min n=5; KU 1h n=5; KU 3h n=5).  
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Evaluation of KU applicability to rescue neuronal 
dysfunctions in the mouse model of Rett syndrome 
 
Genetic lack of Mecp2 results in ATM increased expression 
 
To further confirm the link between ATM and Mecp2 we took advantages of Mecp2y/- 
mice, the mouse model of Rett syndrome. We evaluated ATM expression in P6-7 
Mecp2y/- mice compared to sex matched wild-type (WT). Surprisingly, Western blotting 
experiments showed an increased amount of ATM protein (Figure 18A-B) in association 
with reduced KCC2 levels (Figure 18A-C), as already described in literature [60], in 
hippocampal tissues extracted from Mecp2-deficient P6 young mice with respect to 
controls.   
 
 
 
 
 
 
Figure 18. A) Representative Western Blotting lanes showing ATM increased expression related to KCC2 
low levels in Mecp2-deficient mice and the house-keeping protein calnexin. B) Quantification of ATM 
expression (Mann-Whitney Test, *p=0,042. WT n=9; Mecp2y/- n=13). C) Quantitative analysis of KCC2 
levels (Mann-Whitney Test, *p=0,026. WT n=6; Mecp2y/- n=6).  
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KU rescues functional defects in Mecp2y/- neurons  
 
After demonstrating the capability of KU treatment in modulating KCC2 expression 
and E/I balance, our next goal was to test its efficacy in rescuing pathological phenotypes 
of neurodevelopmental disorders. Since in literature is widely accepted that Rett 
syndrome is characterized by a delayed GABAergic maturation, low KCC2 levels and 
E/I imbalance [60, 69, 71], we evaluated the possibility to exploit KU action to ameliorate 
neuronal defects in Mecp2y/- mice. In addition, we unveiled for the first time that Mecp2 
genetic ablation results in increased ATM expression in mice, suggesting a possible ATM 
implication in Rett aethiopathology. We therefore treated Mecp2y/- neuronal primary 
cultures with the ATM inhibitor KU during development (DIV 7/8) and we performed 
calcium imaging experiments and electrophysiological recordings to evaluate 
respectively excitatory-to-inhibitory switch of GABA and neuronal activity (Figure 19A). 
Calcium imaging data showed a significantly higher percentage of neurons responding to 
GABA stimuli with calcium transients in Mecp2y/- preparations compared to wild-type 
(WT), indicating a still depolarizing action of GABA and a delayed GABA switch in 
Mecp2-deficient mice. This developmental retardation is completely normalized through 
KU application one day prior to calcium imaging experiments (Figure 19B). To exclude 
VOCC changes upon KU treatment in Mecp2y/- cells, we evaluated KCl-induced calcium 
responses, but we observed no changing in amplitude of induced-calcium transients in all 
the experimental conditions (Figure 19C). As displayed in Figure 19D, we also found 
reduced calcium peaks induced by GABA application in Mecp2y/- neurons compared to 
WT, indicating a significant alteration in GABA receptor expression, which is restored 
by KU treatment.  
Finally, the hyperexcitability induced by exposing neurons to a Mg2+-free external 
medium was observed only in 14 DIV Mecp2y/- neuronal cultures, as shown in Figure 
19E-F, by the significantly higher spiking activity (MU frequency) with respect to control 
(KRH external solution). No significant differences in terms of firing frequency could 
instead be detected in Mecp2y/- cells treated with KU during development and then 
exposed to the hyperexcitability paradigm at 14 DIV (Figure 19E-F).  
 
 
79 
 
 
 
 
 
Figure 19. A) Scheme showing the experimental time-line of KU treatment and functional experiments 
carried-out in Mecp2y/- neurons. B) Calcium imaging quantification of the percentage of 8 DIV neurons 
responding to GABA stimuli by depolarization (Kruskal-Wallis followed by Dunn’s Multiple Comparisons 
Test, **p<0,01 - ***p<0,001. WT n=227; Mecp2y/- n=93; Mecp2y/- + KU n=215). C) Analysis of calcium 
transients evoked by KCl application shows no changes in VOCC expression (Kruskal-Wallis followed by 
Dunn’s Multiple Comparisons Test, p=0,292. WT n=227; Mecp2y/- n=93; Mecp2y/- + KU n=215). D) 
Calcium transients upon GABA 100 µM stimulation indicate a lower amount of GABA receptors expression 
in Mecp2y/- cells which is rescued by KU treatment during development (Kruskal-Wallis followed by Dunn’s 
Multiple Comparisons Test, **p<0,01. WT n=58; Mecp2y/- n=40; Mecp2y/-+KU n=34). E) 
Electrophysiological traces of Multi-Unit (MU) activity (i.e. spiking activity) recorded in voltage-clamp in 
cell attached configuration in 14 DIV Mecp2y/- hippocampal cultured neurons, treated or not with KU 
during development, before and after the Mg2+ removal from the external solution. F) Quantification of 
MU frequency displays that Mecp2y/-+KU neurons are resistant in generating the pharmacological 
hyperexcitability induced by Mg2+ removal (One-Way Anova followed by Sidak’s Multiple Comparisons 
Test, ***p<0,001. Mecp2y/- n=17; Mecp2y/- w/o Mg2+ n=16; Mecp2y/-+KU n=18; Mecp2y/-+KU w/o Mg2+ 
n=14).  
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We then investigated the molecular mechanism underlying KU rescuing effect of 
neurological defects in Mecp2y/- neuronal cultures. We took advantage of Luciferase assay 
and we found a potentiated Egr4 activity on Kcc2b promoter (Figure 20A) in accordance 
to normalized KCC2 expression levels (Figure 20B) in Mecp2y/- cells treated with KU.  
Altogether these data strongly suggest that KU tuning of ATM activity could 
represent a novel tool to treat developmental retardation in the mouse model of Rett 
syndrome.  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 20. A) Luciferase analysis indicates that KU treatment potentiates Egr4 activity on Kcc2b promoter 
in Mecp2y/- neurons (Ordinary One-way Anova followed by Tukey’s multiple comparison test, *p<0,05 - 
**p<0,01. Number of samples (isolated embryos) WT n=6; Mecp2y/- n=4; Mecp2y/-+KU n=4). B) 
Biochemical analysis shows KU rescuing effect of KCC2 expression in Mecp2y/- treated neurons (One-Way 
Anova, *p=0,048. WT n=8; Mecp2y/- n=8; Mecp2y/-+KU n=9). 
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DISCUSSION 
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In this study we highlight the importance of ATM kinase activity in the physiological 
development of central neurons, especially, its key role in regulating GABAergic 
maturation, inhibitory transmission and in maintaining the proper excitatory/inhibitory 
balance. We reveal ATM dysregulation as a novel aethiopathological factor responsible 
for neuronal dysfunctions in neurodevelopmental disorders, i.e. Rett syndrome. Notably, 
we demonstrate a completely novel application of the ATM inhibitor KU, a compound 
already used in oncological pre-clinical research, as an innovative pharmacological tool 
for the treatment of neurodevelopmental disorders characterized by altered GABAergic 
maturation, poor inhibition and neuronal hyperexcitability.  
 
The maintenance of a proper balance between excitatory and inhibitory 
neurotransmission is crucial for a the correct brain development, function and plasticity 
[9, 13]. Thus, alterations in GABA developmental steps may result in pathological 
conditions such as epilepsy, autism and schizophrenia [26, 263]. A fundamental process 
in GABAergic maturation is the so called “excitatory-to-inhibitory switch of GABA”, the 
postnatal transition of GABA transmission from excitatory to inhibitory [38]. In our 
previous study we demonstrated an anticipated GABA switch and an increased inhibitory 
tone, associated to higher KCC2 expression levels, in hippocampal neurons established 
from ATM heterozygous embryos [220], suggesting ATM role in controlling neuronal 
development and inhibitory transmission. The aim of this thesis was to investigate the 
possibility to mimic, by a pharmacological intervention, the accelerated GABAergic 
development and potentiated inhibitory tone typical of the ATM heterozygous phenotype, 
to propose a new tool for the treatment of neurological disorders associated with 
developmental alterations and neuronal hyperexcitability.  
 
To verify our hypothesis, we tested the effectiveness of KU, a potent inhibitor of 
ATM kinase activity largely studied in oncology because of its ability to inhibit cancer 
proliferation by inducing apoptosis [227, 230]. We first identified 1 µM as the lowest 
concentration of KU able to inhibit ATM but free from inducing toxic effects in neuronal 
cultures. This is in line with several studies which indicate that i) KU 5 µM is the highest 
non-toxic drug concentrations linked to a cell viability above 85% [242]; ii) KU 2 µM 
does not affect cell survival [243]. Moreover, KU exhibits a potent specificity for ATM 
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kinase with at least a 100-fold differential in selectivity in a counter-screening of KU 
against other members of the PIKK family. Moreover, several studies show that KU 
concentrations up to 10,000 times higher than 1 µM display a good selectivity for ATM 
kinase pathways, i.e. KU 10 mM has no significant effects on unspecific pathways such 
as the CREB transcriptional basal activity [244]. In contrast, in an in vitro study Farkas 
and colleagues demonstrated that KU inhibits autophagy at concentration of 2 µM. They 
excluded ATM kinase involvement in autophagy pathway and they identified Vps34 as a 
direct target of KU [243]. Since we used KU 10 µM for in vivo experiments, we verified 
the possible KU-induced inhibition of basal autophagy in KU injected mice. We checked 
the expression levels of the pivotal autophagy marker, the microtubule-associated protein 
1 light chain 3 BII isoform (LC3-BII) [258, 259], and the Heat Shock Protein Family A 
(Hsp70) Member 8 (HSPA8), an ubiquitous molecular chaperone known to play an 
important role in protein folding and degradation, endosomal micro-autophagy and 
chaperone-mediated autophagy [260, 261]. We did not find any changes in the expression 
of these proteins even if the KU concentration that we applied in vivo is higher than the 
one implicated in the autophagy pathway in vitro. We explain these results by the 
evidence that i) once injected in the ventricle, KU gets diluted so the final effective 
concentration is much lower than 10 µM; ii) starting by the same drug concentration, KU 
will differently impact neuronal function in an in vivo protocol, in which the complexity 
of the brain structure is maintained, compared to an in vitro simplified model; iii) KU 
inhibition of autophagosome formation has been demonstrated in an autophagy-activated 
paradigm whereas we evaluate KU effects in steady-state neurons or mice. Thus, our 
results well combine with the literature. 
 
In our previous publication, we demonstrated a precocious development of inhibitory 
system linked to increased KCC2 expression and higher inhibitory tone in Atm 
heterozygous mice [220]. Taking advantages of the ATM kinase inhibitor KU, in the 
current study we highlight the importance of ATM kinase activity in physiological brain 
development and in neurodevelopmental disorders aetiology. Results collected in this 
thesis provide additional and stronger evidence of the direct link between ATM activity 
– KCC2 expression and inhibition levels, corroborating and expanding what we showed 
in Pizzamiglio et al, 2016 [220]. Moreover, these data reveal that the tuning of ATM 
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activity impacts KCC2 expression only in a restricted temporal window during 
development, which can be defined as “critical period for KCC2 production”. At this 
stage of maturation, the system is particularly sensitive to changes, indeed a short-term 
ATM inhibition, by accelerating the excitatory to inhibitory switch of GABA, induces 
long-lasting effects on neuronal transmission. Coherently, it is widely accepted that a 
perturbation of neuronal development, even if of short duration, can deeply and 
permanently modify neuronal function [264-266].  
 
Importantly, our results disclose the molecular mechanisms underlying ATM 
essential role in the maturation of GABAergic system. Exploiting both the 
pharmacological and the genetic models of ATM deficiency, we demonstrated that ATM 
regulates Kcc2 transcription through two different and independent pathways involving 
the transcription factor Egr4, and the epigenetic regulator Mecp2. Egr4 directly promotes 
KCC2 expression by binding Kcc2b promoter [50, 262], whereas Mecp2, occupying the 
repressor element-1 (RE-1) sites in the Kcc2 gene, prevents REST binding and inhibition 
of KCC2 expression [60]. In presence of reduced but still present ATM activity, i.e. KU-
treated cells/mice and in Atm-Het neurons/mice, both these two mechanisms occur 
leading to higher KCC2 levels, as indicated by the increased Egr4 activity on Kcc2b 
promoter and the higher Mecp2 expression. In Atm-KO, where ATM is completely 
absent, the Egr4 activity is reduced and the higher KCC2 signal is exclusively linked to 
the increased Mecp2 levels. Vice versa, in Mecp2-null brains, in which we found higher 
ATM and reduced KCC2 levels, KU administration normalizes KCC2 expression 
potentiating Egr4 activity. Thus, variations in ATM levels reflect opposed KCC2 
expression and behaviour in terms of GABAergic development based on Egr4 and Mecp2 
dependent-mechanisms. 
 
The results collected in this work acquire relevance since ATM emerges as a new 
potential target to restore the proper excitatory/inhibitory transmission in conditions 
associated to hyperexcitability and delayed GABAergic maturation. In fact, we 
demonstrated that inhibition of ATM activity in Mecp2y/- neurons, the mouse model of 
Rett syndrome, rescues abnormal GABAergic development and normalizes E/I balance 
and neuronal hyperexcitability. As in the case of Rett syndrome, a large number of 
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psychiatric and neurodevelopmental disorders are mainly characterized by E/I imbalance 
and failure of inhibition, as indicated in: i) Oxt-/- mouse model of autism spectrum disorder 
[80, 267]; ii) Scn1a+/- model of a severe epilepsy of infancy, the Dravet syndrome [77]; 
iii) FMRP mice, the mouse model of the Fragile-X syndrome associated to mental 
retardation [268]; iv) heterozygous reeler mice, one of the mouse models of 
schizophrenia [269]; v) Lgdel+/− mouse model of 22q11.2 deletion syndrome (22q11.2 
DS) associated to autism, schizophrenia and cognitive impairments [270]; and so on. 
Thus, ATM tuning could be tested as an innovative treatment in a plethora of neurological 
disorders.  
 
Also, our work perfectly fit with recent studies which highlight the role of proteins 
involved in DNA double-strand breaks (DSBs) machinery as fundamental regulators of 
neuronal function [104, 106]. In particular, it has been demonstrated that diverse 
paradigms of neuronal stimulation, such as mice exposure to physiological learning 
behaviours, determine the formation of DSBs. These activity-dependent DSBs are 
restricted to few loci through the entire genome enriched for the early response genes Fos, 
Npas4, Egr1, and Nr4a, whose induction regulates experience-driven changes to synapses 
including synaptogenesis, neurite outgrowth, synaptic strength and maturation [107]. 
This process seems to be crucial since alterations of this pathway result in cognitive 
disabilities [112]. In this scenario, our present results, provide further proofs that defects 
in DSBs related proteins may generate neurological disfunctions and point out that a 
better understanding of the mechanisms underlying these alterations will be of enormous 
significance.  
 
Finally, this study demonstrates for the first time that among the pathological 
modifications occurred in the mouse model of Rett Syndrome, higher ATM levels 
contribute to the generation of the altered neuronal phenotype. ATM signalling has been 
found consistently elevated also in cells and brains derived from the mouse model of 
Huntington disease (HD) and in HD patients’ brain tissues [118]. Notably, the genetic 
reduction of Atm, reaching by crossing the murine Atm heterozygous null allele onto mice 
expressing full-length human mutant Huntingtin, ameliorates multiple behavioural 
deficits and partially improved HD neuropathology [118]. Also, in two mouse models of 
86 
 
HD, it has been found a reduced KCC2 expression and then a still excitatory action of 
GABA in mature neurons [271], that perfectly fit with the high amount of ATM protein. 
This alteration in inhibitory maturation seems to underlie cognitive defects of HD mouse 
model since restoring proper GABAergic function rescues memory deficits [271]. On the 
other hand, loss-of function mutations in ATM gene, resulting in ATM deficiency, have 
been associated to cognitive impairments among which defects of attention, verbal 
memory, non-verbal memory, late learning and fluency of speech [142]. Coherently, Nora 
D. Volkow and colleagues demonstrated by positron emission tomography a reduced 
glucose metabolism in some brain regions, including the hippocampus, in homozygous 
and heterozygous patients compared to healthy controls [143]. This evidence suggests 
that both increase and decrease of ATM levels correlate with brain changes. Thus, the 
maintenance of a balanced ATM kinase activity is necessary for the correct brain 
maturation and function. Further experiments are needed to better investigate the 
involvement of ATM in the aetiopathogenesis of other neurological diseases such as 
autism spectrum disorders and epilepsy, in which low KCC2 levels and hyperexcitability 
are common pathological features. Mostly, the inhibition of ATM activity in neurological 
diseases through KU offers, as an example of “drug repositioning”, the big benefit to 
shorten time of drug characterization and to exploit an old drug in a new field. 
The results collected in this thesis strongly support our idea to collocate ATM as a 
new key protein responsible for the physiological development of central neurons and 
highlight ATM inhibition as a prospective therapeutic tool in neurodevelopmental 
disorders. 
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